DE69528016D1 - Konjugate von Methyltrithio-Antitumormitteln und Zwischenprodukte für deren Herstellung - Google Patents

Konjugate von Methyltrithio-Antitumormitteln und Zwischenprodukte für deren Herstellung

Info

Publication number: DE69528016D1
Authority: DE; Germany
Prior art keywords: conjugates; carrier; intermediates; manufacture; antitumor agent
Prior art date: 1994-06-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69528016T

Other languages

English (en)

Other versions

DE69528016T2 (de

Inventor

Philip Ross Hamann

Lois Hinman

Irwin Hollander

Ryan Holcomb

Hwei-Ru Tsou

William Hallett

Martin J Weiss

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Wyeth Holdings LLC

Original Assignee

American Cyanamid Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-06-03

Filing date

1995-06-01

Publication date

2002-10-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22962074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69528016(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-06-01 Application filed by American Cyanamid Co filed Critical American Cyanamid Co

2002-10-10 Application granted granted Critical

2002-10-10 Publication of DE69528016D1 publication Critical patent/DE69528016D1/de

2003-01-02 Publication of DE69528016T2 publication Critical patent/DE69528016T2/de

2015-06-02 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

-1 Methyltrithio Chemical group 0.000 title 1
239000002246 antineoplastic agent Substances 0.000 title 1
239000000543 intermediate Substances 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
239000003242 anti bacterial agent Substances 0.000 abstract 2
230000000259 anti-tumor effect Effects 0.000 abstract 2
229940088710 antibiotic agent Drugs 0.000 abstract 2
229940079593 drug Drugs 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
229930189413 Esperamicin Natural products 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 abstract 1
229930195731 calicheamicin Natural products 0.000 abstract 1
239000000969 carrier Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
150000002019 disulfides Chemical class 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
239000003102 growth factor Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
150000003431 steroids Chemical class 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1
230000008685 targeting Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Mycology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Plural Heterocyclic Compounds (AREA)
Treatments Of Macromolecular Shaped Articles (AREA)

DE69528016T 1994-06-03 1995-06-01 Konjugate von Methyltrithio-Antitumormitteln und Zwischenprodukte für deren Herstellung Expired - Lifetime DE69528016T2 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/253,877 US5773001A (en)	1994-06-03	1994-06-03	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis

Publications (2)

Publication Number	Publication Date
DE69528016D1 true DE69528016D1 (de)	2002-10-10
DE69528016T2 DE69528016T2 (de)	2003-01-02

Family

ID=22962074

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69528016T Expired - Lifetime DE69528016T2 (de)	1994-06-03	1995-06-01	Konjugate von Methyltrithio-Antitumormitteln und Zwischenprodukte für deren Herstellung

Country Status (20)

Country	Link
US (4)	US5773001A (de)
EP (1)	EP0689845B1 (de)
JP (2)	JP3650165B2 (de)
KR (1)	KR100408376B1 (de)
AT (1)	ATE223234T1 (de)
AU (1)	AU697280B2 (de)
BR (2)	BR1100990A (de)
CA (1)	CA2150785C (de)
CY (1)	CY2334B1 (de)
DE (1)	DE69528016T2 (de)
DK (1)	DK0689845T3 (de)
ES (1)	ES2181752T3 (de)
FI (1)	FI117690B (de)
IL (1)	IL113984A (de)
NO (1)	NO313617B1 (de)
NZ (3)	NZ272274A (de)
PT (1)	PT689845E (de)
SI (1)	SI0689845T1 (de)
TW (1)	TW394778B (de)
ZA (1)	ZA954570B (de)

Families Citing this family (699)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5773001A (en) *	1994-06-03	1998-06-30	American Cyanamid Company	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5714586A (en) *	1995-06-07	1998-02-03	American Cyanamid Company	Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) *	1995-06-07	1998-01-27	American Cyanamid Company	Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
WO1999039207A1 (en) *	1998-01-29	1999-08-05	Pharmacopeia, Inc.	Acid cleavable phenoxyalkyl linker for combinatorial synthesis
US6008321A (en) *	1998-03-16	1999-12-28	Pharmacopeia, Inc.	Universal linker for combinatorial synthesis
US6914130B2 (en) *	1998-06-17	2005-07-05	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
US6733998B1 (en)	1998-12-07	2004-05-11	Sloan-Kettering Institute For Cancer Research	Micromonospora echinospora genes coding for biosynthesis of calicheamicin and self-resistance thereto
US20050159591A1 (en) *	1999-06-02	2005-07-21	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
CN100340575C (zh)	1999-06-25	2007-10-03	杰南技术公司	人源化抗ErbB2抗体及其在制备药物中的应用
US20040001827A1 (en) *	2002-06-28	2004-01-01	Dennis Mark S.	Serum albumin binding peptides for tumor targeting
WO2001045746A2 (en) *	1999-12-24	2001-06-28	Genentech, Inc.	Methods and compositions for prolonging elimination half-times of bioactive compounds
US20050287153A1 (en) *	2002-06-28	2005-12-29	Genentech, Inc.	Serum albumin binding peptides for tumor targeting
US20060228364A1 (en) *	1999-12-24	2006-10-12	Genentech, Inc.	Serum albumin binding peptides for tumor targeting
US7034121B2 (en) *	2000-01-27	2006-04-25	Genetics Institue, Llc	Antibodies against CTLA4
LT2857516T (lt)	2000-04-11	2017-09-11	Genentech, Inc.	Multivalentiniai antikūnai ir jų panaudojimas
DE60144198D1 (de)	2000-12-28	2011-04-21	Wyeth Llc	Rekombinantes schutzprotein aus streptococcus pneumoniae
US6652853B2 (en) *	2001-03-08	2003-11-25	Ludwig Institute For Cancer Research	Method for treating cancer using A33 specific antibodies and chemotherapeutic agents
NZ511705A (en) *	2001-05-14	2004-03-26	Horticulture & Food Res Inst	Methods and rapid immunoassay device for detecting progesterone and other steroids
CN1463270A (zh)	2001-05-31	2003-12-24	梅达莱克斯公司	细胞毒素、其有用的前体药物、连接基团和稳定剂
US20070160576A1 (en)	2001-06-05	2007-07-12	Genentech, Inc.	IL-17A/F heterologous polypeptides and therapeutic uses thereof
US7803915B2 (en)	2001-06-20	2010-09-28	Genentech, Inc.	Antibody compositions for the diagnosis and treatment of tumor
MXPA03011985A (es)	2001-06-20	2004-03-26	Genentech Inc	Composiciones y metodos para el diagnostico y tratamiento de tumores.
US20050107595A1 (en) *	2001-06-20	2005-05-19	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
US20040086504A1 (en) *	2001-06-21	2004-05-06	Deepak Sampath	Cyr61 as a target for treatment and diagnosis of breast cancer
US20040235068A1 (en) *	2001-09-05	2004-11-25	Levinson Arthur D.	Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
ES2390531T3 (es)	2001-09-18	2012-11-13	Genentech, Inc.	Composiciones y procedimientos para el diagnósitco y tratamiento de tumor
US20040023910A1 (en) *	2001-09-28	2004-02-05	Zhiming Zhang	Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
US20110045005A1 (en)	2001-10-19	2011-02-24	Craig Crowley	Compositions and methods for the treatment of tumor of hematopoietic origin
EP2067472A1 (de)	2002-01-02	2009-06-10	Genentech, Inc.	Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
US20100311954A1 (en) *	2002-03-01	2010-12-09	Xencor, Inc.	Optimized Proteins that Target Ep-CAM
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US20090042291A1 (en) *	2002-03-01	2009-02-12	Xencor, Inc.	Optimized Fc variants
US7662925B2 (en) *	2002-03-01	2010-02-16	Xencor, Inc.	Optimized Fc variants and methods for their generation
NZ535925A (en)	2002-04-16	2008-06-30	Genentech Inc	An isolated antibody that binds to a particular polypeptide
TWI379693B (en)	2002-05-02	2012-12-21	Wyeth Corp	Calicheamicin derivative-carrier conjugates
JP5069843B2 (ja)	2002-07-15	2012-11-07	ジェネンテック，インコーポレイテッド	抗ＥｒｂＢ２抗体を用いる処置に応答性である腫瘍を同定するための方法
BRPI0314814C1 (pt)	2002-09-27	2021-07-27	Xencor Inc	anticorpo compreendendo uma variante de fc
DE60336406D1 (de)	2002-10-16	2011-04-28	Purdue Pharma Lp	Antikörper, die an zellassoziiertes ca 125/0722p binden, und verfahren zu deren anwendung
US20040152632A1 (en) *	2002-11-06	2004-08-05	Wyeth	Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
US20090010920A1 (en) *	2003-03-03	2009-01-08	Xencor, Inc.	Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en)	2003-03-03	2013-03-05	Xencor, Inc.	Fc variants
KR100835786B1 (ko)	2003-07-08	2008-06-09	제넨테크, 인크.	Ｉｌ-１７ａ／ｆ 이종 폴리펩티드 및 그의 치료 용도
CA2532965C (en)	2003-07-22	2013-05-14	Astex Therapeutics Limited	3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
US8038983B2 (en) *	2003-07-29	2011-10-18	Immunomedics, Inc.	Fluorinated carbohydrate conjugates
WO2005012531A2 (en) *	2003-08-01	2005-02-10	Genentech, Inc.	Antibody cdr polypeptide sequences with restricted diversity
US8101720B2 (en) *	2004-10-21	2012-01-24	Xencor, Inc.	Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en)	2003-09-26	2017-07-25	Xencor, Inc.	Optimized Fc variants and methods for their generation
US20050282168A1 (en) *	2003-09-29	2005-12-22	Wyeth	Cell surface molecules as markers and therapeutic agents against kidney cancers
ZA200603619B (en)	2003-11-06	2008-10-29	Seattle Genetics Inc	Monomethylvaline compounds capable of conjugation to ligands
JP4901478B2 (ja)	2003-11-17	2012-03-21	ジェネンテック，インコーポレイテッド	造血系起源の腫瘍の治療のための組成物と方法
PT1718677E (pt)	2003-12-19	2012-07-18	Genentech Inc	Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
TW200539855A (en) *	2004-03-15	2005-12-16	Wyeth Corp	Calicheamicin conjugates
ZA200608130B (en)	2004-03-31	2008-12-31	Genentech Inc	Humanized anti-TGF-beta antibodies
WO2005101017A1 (en) *	2004-04-07	2005-10-27	Genentech, Inc.	Mass spectrometry of antibody conjugates
NZ550934A (en) *	2004-05-19	2010-05-28	Medarex Inc	Chemical linkers and conjugates thereof
US7691962B2 (en) *	2004-05-19	2010-04-06	Medarex, Inc.	Chemical linkers and conjugates thereof
KR20120064120A (ko)	2004-06-01	2012-06-18	제넨테크, 인크.	항체 약물 접합체 및 방법
BRPI0510674A (pt)	2004-07-15	2007-12-26	Xencor Inc	variantes fc otimizadas
EP1771474B1 (de)	2004-07-20	2010-01-27	Genentech, Inc.	Angiopoietin-like 4 protein hemmer kombinationen und deren verwendung
MX2007001064A (es)	2004-07-26	2007-04-12	Genentech Inc	Metodos y composiciones para modular la activacion del factor de crecimiento de hepatocitos.
AU2004224925C1 (en) *	2004-08-30	2011-07-21	Biotest Ag	Immunoconjugates targeting syndecan-1 expressing cells and use thereof
PL1784426T3 (pl)	2004-09-03	2012-04-30	Genentech Inc	Humanizowani antagoniści anty-beta7 i ich zastosowania
PE20100251A1 (es) *	2004-09-10	2010-04-10	Wyeth Corp	Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
NZ580115A (en)	2004-09-23	2010-10-29	Genentech Inc	Cysteine engineered antibody light chains and conjugates
CA2583137A1 (en) *	2004-10-05	2006-04-20	Genentech, Inc.	Therapeutic agents with decreased toxicity
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
US8367805B2 (en) *	2004-11-12	2013-02-05	Xencor, Inc.	Fc variants with altered binding to FcRn
US8546543B2 (en)	2004-11-12	2013-10-01	Xencor, Inc.	Fc variants that extend antibody half-life
US20070135620A1 (en) *	2004-11-12	2007-06-14	Xencor, Inc.	Fc variants with altered binding to FcRn
US8802820B2 (en) *	2004-11-12	2014-08-12	Xencor, Inc.	Fc variants with altered binding to FcRn
DK2325207T3 (en)	2004-11-12	2017-06-06	Xencor Inc	Fc variants with altered binding to FcRn
WO2006060533A2 (en)	2004-12-01	2006-06-08	Genentech, Inc.	Conjugates of 1, 8-bis-naphthalimides with an antibody
EP2230517A1 (de)	2005-01-07	2010-09-22	Diadexus, Inc.	OVR110-Antikörperzusammensetzungen und Verwendungsverfahren dafür
US8404718B2 (en)	2005-01-21	2013-03-26	Astex Therapeutics Limited	Combinations of pyrazole kinase inhibitors
WO2006077428A1 (en)	2005-01-21	2006-07-27	Astex Therapeutics Limited	Pharmaceutical compounds
CN102580084B (zh)	2005-01-21	2016-11-23	健泰科生物技术公司	Her抗体的固定剂量给药
AR054425A1 (es)	2005-01-21	2007-06-27	Astex Therapeutics Ltd	Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
DK1851250T3 (da) *	2005-02-18	2012-07-09	Medarex Inc	Humant monoklonalt antistof mod prostataspecifikt membranantigen (psma)
CN103251946A (zh)	2005-02-23	2013-08-21	健泰科生物技术公司	使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活
US20060204505A1 (en) *	2005-03-08	2006-09-14	Sliwkowski Mark X	Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
CA2604885A1 (en)	2005-04-07	2006-10-19	Guoying Yu	Cacna1e in cancer diagnosis, detection and treatment
JP2008535853A (ja)	2005-04-07	2008-09-04	ノバルティスヴァクシンズアンドダイアグノスティクスインコーポレイテッド	癌関連遺伝子
US7714016B2 (en) *	2005-04-08	2010-05-11	Medarex, Inc.	Cytotoxic compounds and conjugates with cleavable substrates
WO2006132788A2 (en)	2005-06-06	2006-12-14	Genentech, Inc.	Transgenic models for different genes and their use for gene characterization
US20070003559A1 (en) *	2005-07-01	2007-01-04	Wyeth	Methods of determining pharmacokinetics of targeted therapies
WO2007008943A2 (en)	2005-07-08	2007-01-18	Xencor, Inc.	Optimized anti-ep-cam antibodies
AU2006280321A1 (en)	2005-08-15	2007-02-22	Genentech, Inc.	Gene disruptions, compositions and methods relating thereto
CA2624662A1 (en)	2005-09-30	2007-04-12	The Government Of The United States Of America, As Represented By The Se Cretary Of Health And Human Services	Methods and compositions for modulating immune tolerance
CA2624189A1 (en)	2005-10-03	2007-04-12	Xencor, Inc.	Fc variants with optimized fc receptor binding properties
KR20080068084A (ko)	2005-10-26	2008-07-22	메다렉스, 인코포레이티드	씨씨-1065 유사체를 제조하기 위한 방법 및 화합물
US8679490B2 (en)	2005-11-07	2014-03-25	Genentech, Inc.	Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
WO2007059404A2 (en)	2005-11-10	2007-05-24	Medarex, Inc.	Duocarmycin derivatives as novel cytotoxic compounds and conjugates
AU2006335053A1 (en)	2005-11-21	2007-07-19	Genentech, Inc.	Novel gene disruptions, compositions and methods relating thereto
WO2007064919A2 (en) *	2005-12-02	2007-06-07	Genentech, Inc.	Binding polypeptides with restricted diversity sequences
CN105859886A (zh)	2005-12-02	2016-08-17	健泰科生物技术公司	牵涉与il-22和il-22r结合的抗体的组合物和方法
ES2388932T3 (es) *	2005-12-02	2012-10-19	Genentech, Inc.	Polipéptidos de unión y usos de los mismos
US20070160577A1 (en) *	2005-12-06	2007-07-12	Wyeth	Interleukin-11 compositions and methods of use
ES2535856T3 (es)	2005-12-15	2015-05-18	Genentech, Inc.	Métodos y composiciones para dirigirse a la poliubiquitina
DK1973950T3 (en)	2006-01-05	2014-12-15	Genentech Inc	ANTI-EphB4 ANTIBODIES AND METHODS FOR USING SAME
WO2007114979A2 (en)	2006-02-17	2007-10-11	Genentech, Inc.	Gene disruptons, compositions and methods relating thereto
TW200806685A (en) *	2006-02-21	2008-02-01	Wyeth Corp	Processes for the convergent synthesis of calicheamicin derivatives
AU2014202414B2 (en) *	2006-02-21	2016-06-02	Wyeth Llc	Processes for the convergent synthesis of calicheamicin derivatives
AU2012261705B2 (en) *	2006-02-21	2014-02-06	Wyeth Llc	Processes for the convergent synthesis of calicheamicin derivatives
CA2644743C (en)	2006-03-08	2015-05-19	Waldemar Debinski	Soluble monomeric ephrin a1
WO2007106744A2 (en)	2006-03-10	2007-09-20	Wyeth	Anti-5t4 antibodies and uses thereof
AR059851A1 (es)	2006-03-16	2008-04-30	Genentech Inc	Anticuerpos de la egfl7 y metodos de uso
EP2389947A1 (de)	2006-03-23	2011-11-30	Novartis AG	Antitumorzellenantigen-Antikörper-Therapeutika
WO2007126455A2 (en)	2006-04-05	2007-11-08	Genentech, Inc.	Method for using boc/cdo to modulate hedgehog signaling
KR20090010194A (ko)	2006-04-13	2009-01-29	노바티스 백신즈 앤드 다이아그노스틱스, 인크.	암의 치료, 진단 또는 검출 방법
US20090288176A1 (en)	2006-04-19	2009-11-19	Genentech, Inc.	Novel Gene Disruptions, Compositions and Methods Relating Thereto
US20090142259A1 (en) *	2006-05-12	2009-06-04	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
RS53168B (en)	2006-05-30	2014-06-30	Genentech Inc.	Antibodies and Immunoconjugates and Their Use
ES2457072T3 (es)	2006-08-14	2014-04-24	Xencor, Inc.	Anticuerpos optimizados que seleccionan como diana CD19
EP2061906B1 (de)	2006-09-12	2011-08-31	Genentech, Inc.	Verfahren und zusammensetzungen zur diagnose und behandlung von lungenkrebs mittels pdgfra-, kit- oder kdg-gen als genmarker
EP2073807A1 (de)	2006-10-12	2009-07-01	Astex Therapeutics Limited	Pharmazeutische kombinationen
WO2008044041A1 (en)	2006-10-12	2008-04-17	Astex Therapeutics Limited	Pharmaceutical combinations
RS53942B1 (en)	2006-10-27	2015-08-31	Genentech Inc.	Antibodies and Immunoconjugates and Their Use
AU2007325283B2 (en)	2006-11-27	2012-08-30	Diadexus, Inc.	Ovr110 antibody compositions and methods of use
TWI412367B (zh)	2006-12-28	2013-10-21	Medarex Llc	化學鏈接劑與可裂解基質以及其之綴合物
BRPI0806403A2 (pt)	2007-02-09	2011-09-06	Genentech Inc	anticorpo anti-robo4, usode um anticorpo e método de obtenção de imagem
CN101616911A (zh)	2007-02-21	2009-12-30	梅达莱克斯公司	具有单个氨基酸的化学连接物及其偶联物
WO2008109440A2 (en)	2007-03-02	2008-09-12	Genentech, Inc.	Predicting response to a her dimerisation inhibitor based on low her3 expression
EP2474556A3 (de)	2007-03-14	2012-10-17	Novartis AG	APCDD1-Inhibitoren zur Behandlung, Diagnose und Erkennung von Krebs
US7960139B2 (en)	2007-03-23	2011-06-14	Academia Sinica	Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
PL2155248T3 (pl)	2007-04-12	2015-12-31	Brigham & Womens Hospital Inc	Celowanie w ABCB5 w terapii nowotworowej
DK2176298T3 (en) *	2007-05-30	2018-02-12	Xencor Inc	Methods and compositions for inhibiting CD32B-expressing cells
PE20090321A1 (es)	2007-06-04	2009-04-20	Genentech Inc	Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
PL2474557T3 (pl)	2007-07-16	2015-02-27	Genentech Inc	Przeciwciała anty- CD79b i immunokoniugaty i sposoby stosowania
US9845355B2 (en)	2007-07-16	2017-12-19	Genentech, Inc.	Humanized anti-CD79b antibodies and immunoconjugates and methods of use
MX342551B (es)	2007-09-26	2016-10-04	Chugai Pharmaceutical Co Ltd	Region constante de anticuerpo modificada.
US8691222B2 (en)	2007-10-02	2014-04-08	Genentech, Inc.	NLRR-1 antagonists and uses thereof
MX2010005244A (es)	2007-11-12	2010-10-25	Theraclone Sciences Inc	Composiciones y métodos para la terapia y el diagnóstico de influenza.
US20110033476A1 (en) *	2007-11-12	2011-02-10	Theraclone Sciences Inc.	Compositions and methods for the therapy and diagnosis of influenza
TWI468417B (zh)	2007-11-30	2015-01-11	Genentech Inc	抗－ｖｅｇｆ抗體
JP2011508738A (ja) *	2007-12-26	2011-03-17	バイオテスト・アクチエンゲゼルシヤフト	Ｃｄ１３８発現腫瘍細胞のターゲティングを向上させる方法及び剤
MX341344B (es)	2007-12-26	2016-08-16	Biotest Ag	Agentes dirigidos a cd138 y sus usos.
EP4098661A1 (de)	2007-12-26	2022-12-07	Xencor, Inc.	Fc-varianten mit veränderter bindung an fcrn
RU2547939C2 (ru) *	2007-12-26	2015-04-10	Биотест Аг	Иммуноконъюгаты, направленные на cd138, и их применение
WO2009080831A1 (en) *	2007-12-26	2009-07-02	Biotest Ag	Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
BRPI0907046A2 (pt)	2008-01-18	2015-07-28	Medimmune Llc	Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
TWI472339B (zh)	2008-01-30	2015-02-11	Genentech Inc	包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
RU2553566C2 (ru)	2008-01-31	2015-06-20	Дженентек, Инк.	АНТИ-CD79b АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
ES2542308T3 (es) *	2008-03-10	2015-08-04	Theraclone Sciences, Inc.	Composiciones y métodos para la terapia y diagnóstico de infecciones por citomegalovirus
SG2014014138A (en) *	2008-03-31	2014-07-30	Genentech Inc	Compositions and methods for treating and diagnosing asthma
CN104655854A (zh)	2008-04-09	2015-05-27	健泰科生物技术公司	用于免疫相关疾病的治疗的新组合物和方法
AU2009246071B2 (en) *	2008-05-16	2013-10-03	Genentech, Inc.	Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists
DK2318832T3 (da)	2008-07-15	2014-01-20	Academia Sinica	Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
EP2633864A1 (de)	2008-07-25	2013-09-04	The Regents of the University of Colorado	Clip-Hemmer und Verfahren zur Modulation der Immunfunktion
CA2736429A1 (en)	2008-10-01	2010-04-08	Genentech, Inc.	Anti-notch2 antibodies and methods of use
JP2012512261A (ja)	2008-12-17	2012-05-31	ジェネンテック，インコーポレイテッド	Ｃ型肝炎ウイルス併用療法
JP5936112B2 (ja)	2009-02-11	2016-06-15	アルブミディクスアクティーゼルスカブ	アルブミン変異体及び複合体
SI3260136T1 (sl)	2009-03-17	2021-05-31	Theraclone Sciences, Inc.	Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
MA33198B1 (fr)	2009-03-20	2012-04-02	Genentech Inc	Anticorps anti-her di-spécifiques
US8124740B2 (en)	2009-03-25	2012-02-28	Genentech, Inc.	Anti- α5 β1 antibodies and uses thereof
CN102378767B (zh)	2009-03-25	2015-01-14	健泰科生物技术公司	抗-fgfr3抗体及其使用方法
NZ595574A (en)	2009-04-01	2013-11-29	Genentech Inc	Anti-fcrh5 antibodies and immunoconjugates and methods of use
AU2010230563A1 (en)	2009-04-02	2011-09-22	Roche Glycart Ag	Multispecific antibodies comprising full length antibodies and single chain Fab fragments
RU2595379C2 (ru)	2009-04-16	2016-08-27	АббВай Биотерапеутикс Инк.	АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ
WO2010121125A1 (en)	2009-04-17	2010-10-21	Wake Forest University Health Sciences	Il-13 receptor binding peptides
CA2759506A1 (en) *	2009-04-23	2010-10-28	Theraclone Sciences, Inc.	Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
EP2432803A2 (de)	2009-05-20	2012-03-28	Theraclone Sciences, Inc.	Zusammensetzungen und verfahren zur therapie und diagnose von grippe
KR20180056805A (ko)	2009-06-04	2018-05-29	노파르티스 아게	ＩｇＧ 콘쥬게이션을 위한 자리의 확인 방법
SG177265A1 (en)	2009-06-17	2012-02-28	Abbott Biotherapeutics Corp	Anti-vegf antibodies and their uses
JP5918129B2 (ja)	2009-06-22	2016-05-18	メディミューン，エルエルシー	部位特異的共役のための操作されたＦｃ領域
SG178177A1 (en)	2009-07-31	2012-03-29	Genentech Inc	Inhibition of tumor metastasis using bv8- or g-csf-antagonists
DK2473522T3 (en)	2009-09-02	2016-11-28	Genentech Inc	Smoothened MUTANT AND METHODS OF USING THE SAME
WO2011028952A1 (en)	2009-09-02	2011-03-10	Xencor, Inc.	Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
NZ701769A (en)	2009-09-16	2016-06-24	Genentech Inc	Coiled coil and/or tether containing protein complexes and uses thereof
IN2012DN02780A (de)	2009-10-06	2015-09-18	Immunogen Inc
PL2488873T3 (pl)	2009-10-16	2016-01-29	Novartis Ag	Biomarkery odpowiedzi farmakodynamicznej wobec guza
BR112012009245A2 (pt)	2009-10-19	2019-09-24	Genentech Inc	''anticorpo,polinucleotídeo,celula hospedeira,método para fabricar um anticorpo,imunoconjugado,formulação farmacêutica e uso do anticorpo''
KR20120105447A (ko)	2009-10-22	2012-09-25	제넨테크, 인크.	항-헵신 항체 및 그의 사용 방법
RU2539772C2 (ru)	2009-10-22	2015-01-27	Дженентек, Инк.	Способы и композиции для модуляции гепсином стимулирующего макрофаги белка
WO2011056494A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor type iib compositions and methods of use
WO2011056502A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Bone morphogenetic protein receptor type ii compositions and methods of use
TW201122101A (en)	2009-10-28	2011-07-01	Facet Biotech Corp	Anti-EGFR antibodies and their uses
MX2012004793A (es)	2009-10-30	2012-07-20	Novozymes Biopharma Dk As	Variantes de albumina.
ES2636971T3 (es)	2009-11-05	2017-10-10	F. Hoffmann-La Roche Ag	Procedimientos y composición para la secreción de polipéptidos heterógenos
PE20121584A1 (es)	2009-11-30	2012-11-29	Genentech Inc	Composiciones y metodos para el diagnostico y el tratamiento de tumores
US11377485B2 (en)	2009-12-02	2022-07-05	Academia Sinica	Methods for modifying human antibodies by glycan engineering
US10087236B2 (en)	2009-12-02	2018-10-02	Academia Sinica	Methods for modifying human antibodies by glycan engineering
EP2507381A4 (de)	2009-12-04	2016-07-20	Hoffmann La Roche	Multispezifische antikörper, antikörperanaloge, zusammensetzungen und verfahren
PT2949670T (pt)	2009-12-10	2019-05-20	Hoffmann La Roche	Anticorpos que se ligam preferencialmente ao domínio extracelular 4 do csf1r e respetiva utilização
TWI505836B (zh)	2009-12-11	2015-11-01	Genentech Inc	抗－ｖｅｇｆ－ｃ抗體及其使用方法
ES2594893T3 (es)	2009-12-16	2016-12-23	Abbvie Biotherapeutics Inc.	Anticuerpos anti HER2 y sus usos
HUE028629T2 (en)	2009-12-23	2016-12-28	Synimmune Gmbh	Anti-FLT3 antibodies and ways of their use
PL2516465T3 (pl)	2009-12-23	2016-11-30		Przeciwciała anty-bv8 i ich zastosowania
WO2011089211A1 (en)	2010-01-22	2011-07-28	Synimmune Gmbh	Anti-cd133 antibodies and methods of using the same
EP2531206B1 (de)	2010-02-04	2017-05-31	Morphotek, Inc.	Chlorotoxinpolypeptide sowie konjugate und verwendungen davon
US8609092B2 (en)	2010-02-08	2013-12-17	Agensys, Inc.	Antibody drug conjugates (ADC) that bind to 161P2F10B proteins
MX2012008958A (es)	2010-02-18	2012-08-23	Genentech Inc	Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer.
KR20130004579A (ko)	2010-02-23	2013-01-11	제넨테크, 인크.	종양의 진단 및 치료를 위한 조성물 및 방법
BR112012022046A2 (pt)	2010-03-05	2017-02-14	F Hoffamann-La Roche Ag	''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''.
KR101656548B1 (ko)	2010-03-05	2016-09-09	에프. 호프만-라 로슈 아게	인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
CN106432474A (zh)	2010-03-12	2017-02-22	艾伯维生物医疗股份有限公司	Ctla4蛋白和其用途
BR112012022044A2 (pt)	2010-03-24	2020-08-25	Genentech Inc	''anticorpo,imunoconjugado,formulação farmacêutica,uso do anticorpo,método de tratamento,anticorpo biespecifico isolado e célula hospedeira''.
TW201138821A (en)	2010-03-26	2011-11-16	Roche Glycart Ag	Bispecific antibodies
CN106977608A (zh)	2010-04-09	2017-07-25	阿尔布麦狄克斯公司	白蛋白衍生物和变体
WO2011130332A1 (en)	2010-04-12	2011-10-20	Academia Sinica	Glycan arrays for high throughput screening of viruses
TWI586806B (zh)	2010-04-23	2017-06-11	建南德克公司	異多聚體蛋白質之製造
CN107090045A (zh)	2010-05-03	2017-08-25	霍夫曼-拉罗奇有限公司	用于肿瘤诊断和治疗的组合物和方法
WO2011146568A1 (en)	2010-05-19	2011-11-24	Genentech, Inc.	Predicting response to a her inhibitor
AU2011261362B2 (en)	2010-06-03	2016-06-09	Genentech, Inc.	Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
SG10201600791TA (en)	2010-06-08	2016-03-30	Genentech Inc	Cysteine engineered antibodies and conjugates
CN103080136B (zh)	2010-06-18	2015-08-12	霍夫曼-拉罗奇有限公司	抗Axl抗体及使用方法
WO2011161119A1 (en)	2010-06-22	2011-12-29	F. Hoffmann-La Roche Ag	Antibodies against insulin-like growth factor i receptor and uses thereof
WO2011161189A1 (en)	2010-06-24	2011-12-29	F. Hoffmann-La Roche Ag	Anti-hepsin antibodies and methods of use
EP3029066B1 (de)	2010-07-29	2019-02-20	Xencor, Inc.	Antikörper mit modifizierten isoelektrischen punkten
BR112013002535A2 (pt)	2010-08-03	2019-09-24	Hoffmann La Roche	biomarcadores de leucemia linfocítica crônica (cll)
AU2011289275A1 (en)	2010-08-12	2013-02-21	Theraclone Sciences, Inc.	Anti-hemagglutinin antibody compositions and methods of use thereof
AU2011288487B2 (en)	2010-08-13	2015-10-01	Roche Glycart Ag	Anti-FAP antibodies and methods of use
CN104474546A (zh)	2010-08-13	2015-04-01	弗·哈夫曼-拉罗切有限公司	用于疾病治疗的针对IL-1β和IL-18的抗体
MX2013001336A (es)	2010-08-13	2013-03-08	Roche Glycart Ag	Anticuerpos ani-tenascina c a2 y metodos de utilizacion.
CN103068846B9 (zh)	2010-08-24	2016-09-28	弗·哈夫曼-拉罗切有限公司	包含二硫键稳定性Fv片段的双特异性抗体
DK2612151T3 (en)	2010-08-31	2017-10-02	Genentech Inc	BIOMARKETS AND METHODS OF TREATMENT
ES2774369T3 (es)	2010-08-31	2020-07-20	Theraclone Science Int	Anticuerpo de neutralización del virus de la inmunodeficiencia humana
CN103328511B (zh)	2010-09-10	2016-01-20	埃派斯进有限公司	抗-IL-1β抗体及其使用方法
KR20130130709A (ko)	2010-09-29	2013-12-02	어젠시스 인코포레이티드	191p4d12 단백질에 결합하는 항체 약물 컨쥬게이트(ａｄｃ)
WO2012045085A1 (en)	2010-10-01	2012-04-05	Oxford Biotherapeutics Ltd.	Anti-rori antibodies
UA112062C2 (uk) †	2010-10-04	2016-07-25	Бьорінгер Інгельхайм Інтернаціональ Гмбх	Cd33-зв'язувальний агент
AU2011312205B2 (en)	2010-10-05	2015-08-13	Curis, Inc.	Mutant smoothened and methods of using the same
JP6163429B2 (ja)	2010-11-10	2017-07-12	ジェネンテック，インコーポレイテッド	神経疾患免疫治療のための方法及び組成物
WO2012065161A2 (en)	2010-11-12	2012-05-18	Scott & White Healthcare	Antibodies to tumor endothelial marker 8
NZ609493A (en)	2010-12-16	2015-11-27	Genentech Inc	Diagnosis and treatments relating to th2 inhibition
EA028744B1 (ru)	2010-12-20	2017-12-29	Дженентек, Инк.	Антитела против мезотелина и иммуноконъюгаты
KR20130118925A (ko)	2010-12-22	2013-10-30	제넨테크, 인크.	항-pcsk9 항체 및 사용 방법
EP2655413B1 (de)	2010-12-23	2019-01-16	F.Hoffmann-La Roche Ag	Polypeptid-polynukleotid-komplex und verwendung bei der gezielten effektorrest-bereitstellung
JOP20210044A1 (ar)	2010-12-30	2017-06-16	Takeda Pharmaceuticals Co	الأجسام المضادة لـ cd38
WO2012092539A2 (en)	2010-12-31	2012-07-05	Takeda Pharmaceutical Company Limited	Antibodies to dll4 and uses thereof
US10689447B2 (en)	2011-02-04	2020-06-23	Genentech, Inc.	Fc variants and methods for their production
BR112013019499B1 (pt)	2011-02-04	2023-01-10	Genentech, Inc.	Proteína heteromultimérica variante ou anticorpo igg modificado, método para produzir uma proteína heteromultimérica variante ou anticorpo igg modificado, composição, método para preparar uma proteína heteromultimérica e proteína heteromultimérica variante
US20120213781A1 (en)	2011-02-11	2012-08-23	Zyngenia, Inc.	Monovalent and Multivalent Multispecific Complexes and Uses Thereof
EP2675478A4 (de)	2011-02-14	2015-06-10	Theraclone Sciences Inc	Zusammensetzungen und verfahren zur therapie und diagnose von grippe
JP6097702B2 (ja)	2011-03-03	2017-03-15	アペクシジェン，インコーポレイテッド	抗ｉｌ−６受容体抗体およびその使用方法
JP5832559B2 (ja)	2011-03-10	2015-12-16	オメロスコーポレーション	ｅｘｖｉｖｏにおける加速された抗体進化による抗ＦＮ１４モノクローナル抗体の生成
SG193402A1 (en)	2011-03-15	2013-10-30	Theraclone Sciences Inc	Compositions and methods for the therapy and diagnosis of influenza
EP3138581B1 (de)	2011-03-17	2019-01-02	The University of Birmingham	Umgelenkte immuntherapie
MX354359B (es)	2011-03-29	2018-02-28	Roche Glycart Ag	Variantes de fragmento cristalizable (fc) de los anticuerpos.
RU2013143358A (ru)	2011-04-07	2015-05-20	Дженентек, Инк.	Анти-fgfr4 антитела и способы их применения
BR112013026423A2 (pt)	2011-04-20	2016-11-29	Roche Glycart Ag	método e construtos para a passagem de pendente do ph da barreira sangue-cérebro
BR112013027829B1 (pt)	2011-04-29	2022-05-10	Apexigen, Inc	Anticorpos anti-cd40 ou fragmentos de ligação aos antígenos destes, composição que compreende os ditos anticorpos e uso da dita composição para tratar ou melhorar os sintomas de câncer, doença autoimune ou doença inflamatória
PE20140995A1 (es)	2011-05-16	2014-08-23	Genentech Inc	Agonistas de fgfr1 y sus metodos de uso
CA2837169C (en)	2011-05-24	2021-11-09	Zyngenia, Inc.	Multispecific complexes comprising angiopoietin-2-binding peptide and their uses
MX351069B (es)	2011-05-27	2017-09-29	Glaxo Group Ltd	Proteinas de union abcma (cd269/tnfrsf17).
TWI597065B (zh)	2011-06-10	2017-09-01	梅爾莎納醫療公司	蛋白質－聚合物－藥物共軛體
WO2013003507A1 (en)	2011-06-27	2013-01-03	Morphotek, Inc.	Multifunctional agents
AR086823A1 (es)	2011-06-30	2014-01-22	Genentech Inc	Formulaciones de anticuerpo anti-c-met, metodos
WO2013022855A1 (en)	2011-08-05	2013-02-14	Xencor, Inc.	Antibodies with modified isoelectric points and immunofiltering
JP5944994B2 (ja)	2011-08-12	2016-07-05	オメロスコーポレーション	抗ｆｚｄ１０モノクローナル抗体およびそれらの使用方法
CA2842375A1 (en)	2011-08-17	2013-02-21	Erica Jackson	Neuregulin antibodies and uses thereof
RU2014109985A (ru)	2011-08-17	2015-09-27	Дженентек, Инк.	Ингибирование ангиогенеза в рефрактерных опухолях
WO2013026839A1 (en)	2011-08-23	2013-02-28	Roche Glycart Ag	Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
KR101723273B1 (ko)	2011-08-23	2017-04-04	로슈 글리카트 아게	2 개의 ｆａｂ 단편을 포함하는 fc-부재 항체 및 이용 방법
US8822651B2 (en)	2011-08-30	2014-09-02	Theraclone Sciences, Inc.	Human rhinovirus (HRV) antibodies
MX2014003094A (es)	2011-09-15	2014-04-25	Genentech Inc	Metodos para promover diferenciacion.
CN103930111A (zh)	2011-09-19	2014-07-16	霍夫曼-拉罗奇有限公司	包含c-met拮抗剂和b-raf拮抗剂的组合治疗
BR112014006537A2 (pt)	2011-09-23	2017-11-28	Roche Glycart Ag	anticorpos biespecíficos, formulação farmacêutica, usos de um anticorpo biespecífico, método de tratamento, ácido nucleico, vetores de expressão, célula hospedeira e método para a produção de um anticorpo biespecífico
US9663573B2 (en)	2011-10-05	2017-05-30	Genentech, Inc.	Methods of treating liver conditions using Notch2 antagonists
US10851178B2 (en)	2011-10-10	2020-12-01	Xencor, Inc.	Heterodimeric human IgG1 polypeptides with isoelectric point modifications
DK2766392T3 (da)	2011-10-10	2019-10-07	Xencor Inc	Fremgangsmåde til oprensning af antistoffer
CN106977587A (zh)	2011-10-14	2017-07-25	霍夫曼-拉罗奇有限公司	Bace1的肽抑制剂
US9738727B2 (en)	2011-10-14	2017-08-22	Genentech, Inc.	Anti-HtrA1 antibodies and methods of use
WO2013056148A2 (en)	2011-10-15	2013-04-18	Genentech, Inc.	Methods of using scd1 antagonists
CA2853705C (en)	2011-10-25	2021-10-12	Memorial Sloan-Kettering Cancer Center	Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer
SG11201401815XA (en)	2011-10-28	2014-05-29	Genentech Inc	Therapeutic combinations and methods of treating melanoma
WO2013067098A1 (en)	2011-11-02	2013-05-10	Apexigen, Inc.	Anti-kdr antibodies and methods of use
EP2589609A1 (de)	2011-11-03	2013-05-08	Pierre Fabre Medicament	Antigenbindendes Protein und dessen Verwendung als Adressierungsprodukt bei der Behandlung von Krebs
WO2013075066A2 (en)	2011-11-18	2013-05-23	Eleven Biotherapeutics, Inc.	Proteins with improved half-life and other properties
RU2014124842A (ru)	2011-11-21	2015-12-27	Дженентек, Инк.	Очистка анти-с-мет антител
ES2684950T3 (es)	2011-12-08	2018-10-05	Biotest Ag	Usos de inmunoconjugados dirigidos a CD138
US10023643B2 (en)	2011-12-15	2018-07-17	Hoffmann-La Roche Inc.	Antibodies against human CSF-1R and uses thereof
EP2793941A1 (de)	2011-12-23	2014-10-29	F.Hoffmann-La Roche Ag	Hergestellter artikel und verfahren zur co-verabreichung von antikörpern
CN104411717A (zh)	2012-01-09	2015-03-11	斯克利普斯研究所	具有超长cdr3s的人源化抗体
AU2013208003B2 (en)	2012-01-09	2017-12-14	The Scripps Research Institute	Ultralong complementarity determining regions and uses thereof
JP6242813B2 (ja)	2012-01-18	2017-12-06	ジェネンテック，インコーポレイテッド	抗ｌｒｐ５抗体及び使用方法
WO2013109856A2 (en)	2012-01-18	2013-07-25	Genentech, Inc.	Methods of using fgf19 modulators
WO2013116686A1 (en)	2012-02-02	2013-08-08	Massachusetts Institute Of Technology	Methods and products related to targeted cancer therapy
MX2014009565A (es)	2012-02-10	2014-11-10	Genentech Inc	Anticuerpos monocatenarios y otros heteromultimeros.
CN113398268A (zh)	2012-02-11	2021-09-17	霍夫曼-拉罗奇有限公司	R-spondin易位及其使用方法
WO2013120929A1 (en)	2012-02-15	2013-08-22	F. Hoffmann-La Roche Ag	Fc-receptor based affinity chromatography
GB201203442D0 (en)	2012-02-28	2012-04-11	Univ Birmingham	Immunotherapeutic molecules and uses
EP2825556B1 (de)	2012-03-16	2018-01-03	Albumedix A/S	Albuminvarianten
US10024860B2 (en)	2012-03-28	2018-07-17	Massachusetts Institute Of Technology	Cancer-related extracellular matrix signatures and related methods and products
WO2013148259A1 (en)	2012-03-28	2013-10-03	Massachusetts Institute Of Technology	Cancer-related extracellular matrix signatures and related methods and products
AR090549A1 (es)	2012-03-30	2014-11-19	Genentech Inc	Anticuerpos anti-lgr5 e inmunoconjugados
US10130714B2 (en)	2012-04-14	2018-11-20	Academia Sinica	Enhanced anti-influenza agents conjugated with anti-inflammatory activity
WO2013165940A1 (en)	2012-05-01	2013-11-07	Genentech, Inc.	Anti-pmel17 antibodies and immunoconjugates
WO2013170191A1 (en)	2012-05-11	2013-11-14	Genentech, Inc.	Methods of using antagonists of nad biosynthesis from nicotinamide
WO2013188855A1 (en)	2012-06-15	2013-12-19	Genentech, Inc.	Anti-pcsk9 antibodies, formulations, dosing, and methods of use
MX2014014065A (es)	2012-06-27	2015-02-04	Hoffmann La Roche	Metodo para la seleccion y produccion de moleculas terapeuticas hechas a la medida, selectivas y multiespecificas que comprenden al menos dos diferentes entidades de direccionamiento y usos de las mismas.
KR20150023889A (ko)	2012-06-27	2015-03-05	에프. 호프만-라 로슈 아게	2 개 이상의 상이한 결합 단위를 함유하는 맞춤-제작된 고도로 선별적이고 다중-특이적인 표적화 단위의 선별 및 제조 방법 및 이의 용도
RU2015100656A (ru)	2012-06-27	2016-08-20	Ф. Хоффманн-Ля Рош Аг	Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
SG11201407420RA (en)	2012-07-04	2015-02-27	Hoffmann La Roche	Covalently linked antigen-antibody conjugates
RU2630296C2 (ru)	2012-07-04	2017-09-06	Ф. Хоффманн-Ля Рош Аг	Антитела к биотину и способы их применения
RU2630664C2 (ru)	2012-07-04	2017-09-11	Ф. Хоффманн-Ля Рош Аг	Антитела к теофиллину и способы их применения
WO2014009465A1 (en)	2012-07-13	2014-01-16	Roche Glycart Ag	Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
AU2013306098A1 (en)	2012-08-18	2015-02-12	Academia Sinica	Cell-permeable probes for identification and imaging of sialidases
KR102355959B1 (ko)	2012-08-23	2022-01-27	어젠시스 인코포레이티드	158p1d7 단백질에 결합하는 항체 약물 컨쥬게이트(ａｄｃ)
WO2014047222A2 (en)	2012-09-19	2014-03-27	Abbvie Biotherapeutics Inc.	Methods for identifying antibodies with reduced immunogenicity
EP2904016B1 (de)	2012-10-08	2018-11-14	Roche Glycart AG	Fc-freie antikörper mit zwei fab-fragmenten sowie verwendungsverfahren dafür
EP3632471A1 (de)	2012-10-11	2020-04-08	Daiichi Sankyo Company, Limited	Antikörper-wirkstoff-konjugat
JP6272230B2 (ja)	2012-10-19	2018-01-31	第一三共株式会社	親水性構造を含むリンカーで結合させた抗体−薬物コンジュゲート
AU2013334102B2 (en)	2012-10-26	2018-08-16	Memorial Sloan-Kettering Cancer Center	Modulators of resistant androgen receptor
NZ707086A (en)	2012-10-30	2019-07-26	Apexigen Inc	Anti-cd40 antibodies and methods of use
JP6694712B2 (ja)	2012-11-01	2020-05-20	マックス−デルブルック−セントラムフアーモレキュラーレメデジン	Ｃｄ２６９（ｂｃｍａ）に対する抗体
TWI609887B (zh)	2012-11-05	2018-01-01	皮爾法伯製藥公司	新穎的抗原結合蛋白及其作爲治療癌症之定址產物的用途
AR093378A1 (es)	2012-11-08	2015-06-03	Hoffmann La Roche	PROTEINAS LIGANTES DE ANTIGENO HER3 DE UNION A LA HORQUILLA b DE HER3
CA2890766A1 (en)	2012-11-08	2014-05-15	Novozymes Biopharma Dk A/S	Albumin variants
EA201892509A1 (ru)	2012-11-13	2019-04-30	Дженентек, Инк.	Антитела к гемагглютинину и способы применения
ES2701076T3 (es)	2012-11-24	2019-02-20	Hangzhou Dac Biotech Co Ltd	Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
US20140154255A1 (en)	2012-11-30	2014-06-05	Abbvie Biotherapeutics Inc.	Anti-vegf antibodies and their uses
WO2014093394A1 (en)	2012-12-10	2014-06-19	Mersana Therapeutics, Inc.	Protein-polymer-drug conjugates
EP2931316B1 (de)	2012-12-12	2019-02-20	Mersana Therapeutics, Inc.	Hydroxylpolymer-heilmittelproteinkonjugate
WO2014107739A1 (en)	2013-01-07	2014-07-10	Eleven Biotherapeutics, Inc.	Antibodies against pcsk9
US9701759B2 (en)	2013-01-14	2017-07-11	Xencor, Inc.	Heterodimeric proteins
US10131710B2 (en)	2013-01-14	2018-11-20	Xencor, Inc.	Optimized antibody variable regions
US11053316B2 (en)	2013-01-14	2021-07-06	Xencor, Inc.	Optimized antibody variable regions
CA3211863A1 (en)	2013-01-14	2014-07-17	Xencor, Inc.	Novel heterodimeric proteins
US10968276B2 (en)	2013-03-12	2021-04-06	Xencor, Inc.	Optimized anti-CD3 variable regions
US9605084B2 (en)	2013-03-15	2017-03-28	Xencor, Inc.	Heterodimeric proteins
US10487155B2 (en)	2013-01-14	2019-11-26	Xencor, Inc.	Heterodimeric proteins
AU2014207549B2 (en)	2013-01-15	2018-12-06	Xencor, Inc.	Rapid clearance of antigen complexes using novel antibodies
CA2900097A1 (en)	2013-02-22	2014-08-28	F. Hoffmann-La Roche Ag	Methods of treating cancer and preventing drug resistance
US20140242083A1 (en)	2013-02-26	2014-08-28	Roche Glycart Ag	Anti-mcsp antibodies
EP2964260A2 (de)	2013-03-06	2016-01-13	F. Hoffmann-La Roche AG	Verfahren zur behandlung und prävention einer antikrebsmittelresistenz
US9562099B2 (en)	2013-03-14	2017-02-07	Genentech, Inc.	Anti-B7-H4 antibodies and immunoconjugates
JP6436965B2 (ja)	2013-03-14	2018-12-12	ジェネンテック，インコーポレイテッド	抗ｂ７−ｈ４抗体及びイムノコンジュゲート
CN105307683A (zh)	2013-03-14	2016-02-03	基因泰克公司	治疗癌症和预防癌症药物抗性的方法
BR112015023120A2 (pt)	2013-03-15	2017-11-21	Genentech Inc	método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
KR102561553B1 (ko)	2013-03-15	2023-07-31	젠코어 인코포레이티드	이형이량체 단백질
AU2014233503A1 (en)	2013-03-15	2015-09-24	Abbvie Biotechnology Ltd.	Anti-CD25 antibodies and their uses
BR112015023203A8 (pt)	2013-03-15	2018-01-23	Constellation Pharmaceuticals Inc	métodos para tratamento de câncer, método para aumentar a eficiência de um tratamento de câncer, método para retardar e/ou prevenir o desenvolvimento de câncer, método para tratar um indivíduo com câncer, método para aumentar a sensibilidade para um agente de terapia para câncer, método para estender um período de sensibilidade e método para estender a duração da resposta para uma terapia para câncer.
US10519242B2 (en)	2013-03-15	2019-12-31	Xencor, Inc.	Targeting regulatory T cells with heterodimeric proteins
US9598485B2 (en)	2013-03-15	2017-03-21	Ac Immune S.A.	Anti-tau antibodies and methods of use
BR112015023752B1 (pt)	2013-03-15	2023-11-14	Zyngenia, Inc.	Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
US10544187B2 (en)	2013-03-15	2020-01-28	Xencor, Inc.	Targeting regulatory T cells with heterodimeric proteins
BR112015023084A2 (pt)	2013-03-15	2017-11-21	Abbvie Biotechnology Ltd	anticorpo anti-cd25 monoclonal ou um fragmento ligante anti-cd25 de um anticorpo monoclonal, conjugado de anticorpo-droga, composição farmacêutica, ácido nucleico, vetor, célula hospedeira procariota e eucariota, método para a produção de um anticorpo anti-cd25 ou fragmento ligante anti-cd25, e, uso de um anticorpo anti-cd25 monoclonal de um conjugado anticorpo-droga ou de uma composição farmacêutica
CN105143265A (zh)	2013-03-15	2015-12-09	豪夫迈·罗氏有限公司	抗CRTh2抗体及其用途
US10858417B2 (en)	2013-03-15	2020-12-08	Xencor, Inc.	Heterodimeric proteins
US20140377253A1 (en)	2013-03-15	2014-12-25	Abbvie Biotherapeutics Inc.	Fc variants
US10106624B2 (en)	2013-03-15	2018-10-23	Xencor, Inc.	Heterodimeric proteins
KR20150128707A (ko)	2013-03-15	2015-11-18	제넨테크, 인크.	간암의 진단 및 치료를 위한 조성물 및 방법
AR095882A1 (es)	2013-04-22	2015-11-18	Hoffmann La Roche	Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
RU2019108429A (ru)	2013-04-29	2019-05-06	Ф. Хоффманн-Ля Рош Аг	Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения
WO2014179657A1 (en)	2013-05-03	2014-11-06	Eleven Biotherapeutics, Inc.	Albumin variants binding to fcrn
JP6612214B2 (ja)	2013-05-20	2019-11-27	ジェネンテック，インコーポレイテッド	抗トランスフェリン受容体抗体及び使用方法
EP3013365B1 (de)	2013-06-26	2019-06-05	Academia Sinica	Rm2-antigene und verwendung davon
WO2014210564A1 (en)	2013-06-27	2014-12-31	Academia Sinica	Glycan conjugates and use thereof
AU2014290361B2 (en)	2013-07-18	2019-04-18	Taurus Biosciences, Llc	Humanized antibodies with ultralong complementarity determining regions
EP3022224A2 (de)	2013-07-18	2016-05-25	Fabrus, Inc.	Antikörper mit ultralangen komplementaritätsbestimmenden regionen
RU2679657C2 (ru)	2013-08-01	2019-02-12	Эдженсис, Инк.	Конъюгаты антител с лекарственными средствами, связывающиеся с белками cd37
WO2015035044A2 (en)	2013-09-04	2015-03-12	Abbvie Biotherapeutics Inc.	Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
CN105682666B (zh)	2013-09-06	2021-06-01	中央研究院	使用醣脂激活人类iNKT细胞
AR097584A1 (es)	2013-09-12	2016-03-23	Hoffmann La Roche	Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
MX2016003248A (es)	2013-09-17	2016-06-07	Genentech Inc	Metodos de uso de anticuerpos anti-lgr5.
CA2926087C (en)	2013-10-10	2023-03-14	Beth Israel Deaconess Medical Center, Inc.	Tm4sf1 binding proteins and methods of using same
WO2015054659A1 (en)	2013-10-11	2015-04-16	Mersana Therapeutics, Inc.	Protein-polymer-drug conjugates
WO2015054669A1 (en)	2013-10-11	2015-04-16	Asana Biosciences, Llc	Protein-polymer-drug conjugates
US10081682B2 (en)	2013-10-11	2018-09-25	Oxford Bio Therapeutics Ltd.	Conjugated antibodies against LY75 for the treatment of cancer
CA2925598A1 (en)	2013-10-18	2015-04-23	Genentech, Inc.	Anti-rspo antibodies and methods of use
JP2016540826A (ja)	2013-11-04	2016-12-28	ファイザー・インク	抗ｅｆｎａ４抗体−薬物コンジュゲート
PT3066074T (pt) *	2013-11-04	2020-02-03	Pfizer	Intermediários e métodos para sintetizar derivados de caliqueamicina
CA2931340A1 (en)	2013-12-13	2015-06-18	Genentech, Inc.	Anti-cd33 antibodies and immunoconjugates
KR20170042495A (ko)	2013-12-16	2017-04-19	제넨테크, 인크.	펩티드모방체 화합물 및 그의 항체-약물 접합체
US10113169B2 (en)	2013-12-23	2018-10-30	Memorial Sloan-Kettering Cancer Center	Methods and compositions for treating cancer using peptide nucleic acid-based agents
TWI728373B (zh)	2013-12-23	2021-05-21	美商建南德克公司	抗體及使用方法
KR102278429B1 (ko)	2014-01-03	2021-07-16	에프. 호프만-라 로슈 아게	공유 연결된 폴리펩티드 독소-항체 콘쥬게이트
CN105873615B (zh)	2014-01-03	2020-12-25	豪夫迈·罗氏有限公司	共价连接的helicar-抗helicar抗体缀合物及其用途
KR20160104628A (ko)	2014-01-03	2016-09-05	에프. 호프만-라 로슈 아게	이중특이성 항-합텐/항-혈액뇌장벽 수용체 항체, 그의 복합체 및 혈액뇌장벽 셔틀로서 그의 용도
US10150818B2 (en)	2014-01-16	2018-12-11	Academia Sinica	Compositions and methods for treatment and detection of cancers
EP3094352B1 (de)	2014-01-16	2020-09-23	Academia Sinica	Zusammensetzungen und verfahren zur behandlung und zum nachweis von krebs
KR20160111469A (ko)	2014-01-24	2016-09-26	제넨테크, 인크.	항-steap1 항체 및 면역접합체를 사용하는 방법
RU2685728C2 (ru)	2014-01-29	2019-04-23	Шанхай Хэнжуй Фармасьютикал Ко., Лтд.	Конъюгат лиганд - цитотоксическое лекарственное средство, способ его получения и его применения
CA2937539A1 (en)	2014-02-04	2015-08-13	Genentech, Inc.	Mutant smoothened and methods of using the same
SG10201808259TA (en)	2014-02-12	2018-10-30	Genentech Inc	Anti-jagged1 antibodies and methods of use
EP3107574A2 (de)	2014-02-21	2016-12-28	F. Hoffmann-La Roche AG	Anti-il-13/il-17 bispezifische antikörper und verwendungen davon
CN114262344A (zh)	2014-02-28	2022-04-01	杭州多禧生物科技有限公司	带电荷链接体及其在共轭反应上的应用
CN106103730B (zh)	2014-03-14	2021-06-08	豪夫迈·罗氏有限公司	用于分泌异源多肽的方法和组合物
TW202214691A (zh)	2014-03-21	2022-04-16	美商艾伯維有限公司	抗-egfr抗體及抗體藥物結合物
JP2017516458A (ja)	2014-03-24	2017-06-22	ジェネンテック，インコーポレイテッド	ｃ−ｍｅｔ拮抗剤による癌治療及びｃ−ｍｅｔ拮抗剤のＨＧＦ発現との相関
TWI687428B (zh)	2014-03-27	2020-03-11	中央研究院	反應性標記化合物及其用途
AU2015237184B2 (en)	2014-03-28	2020-11-26	Xencor, Inc.	Bispecific antibodies that bind to CD38 and CD3
KR20160145624A (ko)	2014-03-31	2016-12-20	제넨테크, 인크.	항-ox40 항체 및 사용 방법
EP3126386A1 (de)	2014-03-31	2017-02-08	F. Hoffmann-La Roche AG	Kombinationstherapie mit antiangiogenesewirkstoffen und ox40-bindenden agonisten
CN106232139A (zh)	2014-04-11	2016-12-14	免疫医疗有限责任公司	双特异性her2抗体
EP3134438B1 (de)	2014-04-25	2020-09-30	Pierre Fabre Medicament	Igf-1r-antikörper und dessen verwendung als adressierungsmedium bei der behandlung von krebs
PT3137114T (pt)	2014-04-30	2021-02-26	Pfizer	Conjugados anticorpo-fármaco anti-ptk7
CN106471117A (zh)	2014-05-06	2017-03-01	豪夫迈·罗氏有限公司	使用哺乳动物细胞产生异多聚体蛋白
RU2016150370A (ru)	2014-05-22	2018-06-26	Дженентек, Инк.	Антитела и иммуноконъюгаты против GPC3
WO2015179835A2 (en)	2014-05-23	2015-11-26	Genentech, Inc.	Mit biomarkers and methods using the same
US10118969B2 (en)	2014-05-27	2018-11-06	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
AU2015267052A1 (en)	2014-05-27	2016-12-15	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR20220151036A (ko)	2014-05-27	2022-11-11	아카데미아 시니카	항-ｃｄ20 글리코항체 및 이의 용도
AU2015267045B2 (en)	2014-05-27	2021-02-25	Academia Sinica	Anti-HER2 glycoantibodies and uses thereof
US11332523B2 (en)	2014-05-28	2022-05-17	Academia Sinica	Anti-TNF-alpha glycoantibodies and uses thereof
US20230190750A1 (en)	2014-06-13	2023-06-22	Genentech, Inc.	Methods of treating and preventing cancer drug resistance
EP3164419A1 (de)	2014-06-26	2017-05-10	F. Hoffmann-La Roche AG	Anti-brdu-antikörper und verfahren zur verwendung
RU2017103289A (ru)	2014-07-11	2018-08-14	Дженентек, Инк.	Ингибирование пути notch
WO2016014984A1 (en)	2014-07-24	2016-01-28	Xencor, Inc.	Rapid clearance of antigen complexes using novel antibodies
RU2764074C2 (ru)	2014-08-28	2022-01-13	Байоатла, Ллк	Условно активные химерные антигенные рецепторы для модифицированных т-клеток
TWI751102B (zh)	2014-08-28	2022-01-01	美商奇諾治療有限公司	對ｃｄ１９具專一性之抗體及嵌合抗原受體
CN107001404B (zh)	2014-09-08	2021-06-29	中央研究院	使用醣脂激活人类iNKT细胞
AU2015314744A1 (en)	2014-09-12	2017-03-02	Genentech, Inc.	Anti-CLL-1 antibodies and immunoconjugates
AU2015314826A1 (en)	2014-09-12	2017-03-02	Genentech, Inc.	Cysteine engineered antibodies and conjugates
MA40576B1 (fr)	2014-09-12	2020-11-30	Genentech Inc	Anticorps et immunoconjugués anti-her2
CN113698488A (zh)	2014-09-12	2021-11-26	基因泰克公司	抗-b7-h4抗体及免疫缀合物
PL3262071T3 (pl)	2014-09-23	2020-08-10	F. Hoffmann-La Roche Ag	Sposób stosowania immunokoniugatów anty-CD79b
WO2016054315A1 (en)	2014-10-01	2016-04-07	Medimmune, Llc	Method of conjugating a polypeptide
US9732148B2 (en)	2014-10-16	2017-08-15	Genentech, Inc.	Anti-α-synuclein antibodies and methods of use
WO2016063959A1 (ja)	2014-10-24	2016-04-28	日油株式会社	環状ベンジリデンアセタールリンカーを有する抗体―薬物複合体
EP3212665A2 (de)	2014-10-31	2017-09-06	F. Hoffmann-La Roche AG	Kreuzreaktive anti-il-17a- und il-17f-antikörpervarianten und zusammensetzungen sowie verfahren zur herstellung und verwendung davon
CA2966523A1 (en)	2014-11-03	2016-05-12	Genentech, Inc.	Assays for detecting t cell immune subsets and methods of use thereof
US20160160290A1 (en)	2014-11-03	2016-06-09	Genentech, Inc.	Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
BR112017008666A2 (pt)	2014-11-05	2018-01-30	Genentech, Inc.	anticorpos anti-fgfr2/3 e métodos de uso dos mesmos
EP3215528B1 (de)	2014-11-06	2019-08-07	F.Hoffmann-La Roche Ag	Fc-region-varianten mit modifizierte fcrn-bindung und verfahren zur verwendung
WO2016073157A1 (en)	2014-11-06	2016-05-12	Genentech, Inc.	Anti-ang2 antibodies and methods of use thereof
CN107172879B (zh)	2014-11-10	2021-11-05	豪夫迈·罗氏有限公司	抗白细胞介素-33抗体及其用途
EP3221361B1 (de)	2014-11-19	2021-04-21	Genentech, Inc.	Multispezifische anti-transferrin-rezeptor- / anti-bace1-antikörper und verfahren zur verwendung
EP3845565A3 (de)	2014-11-19	2021-09-08	Genentech, Inc.	Antikörper gegen bace1 und verwendung davon zur immuntherapie bei neuronalen erkrankungen
JP6779876B2 (ja)	2014-11-19	2020-11-04	ジェネンテック，インコーポレイテッド	抗トランスフェリン受容体抗体及びその使用方法
CU24597B1 (es)	2014-11-26	2022-05-11	Xencor Inc	Anticuerpos biespecíficos heterodiméricos que se unen a cd3 y cd20
US10259887B2 (en)	2014-11-26	2019-04-16	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and tumor antigens
TN2017000222A1 (en)	2014-11-26	2018-10-19	Xencor Inc	Heterodimeric antibodies that bind cd3 and cd38
WO2016087416A1 (en)	2014-12-03	2016-06-09	F. Hoffmann-La Roche Ag	Multispecific antibodies
LT3227336T (lt)	2014-12-05	2019-09-25	F. Hoffmann-La Roche Ag	Anti-cd79b antikūnai ir jų naudojimo būdai
KR20170085595A (ko)	2014-12-10	2017-07-24	제넨테크, 인크.	혈뇌 장벽 수용체 항체 및 사용 방법
AU2015365167B2 (en)	2014-12-19	2021-07-29	Chugai Seiyaku Kabushiki Kaisha	Anti-C5 antibodies and methods of use
PT3233910T (pt)	2014-12-19	2020-03-17	Ablynx Nv	Dímeros de nanocorpos ligados a cisteína
US10428155B2 (en)	2014-12-22	2019-10-01	Xencor, Inc.	Trispecific antibodies
US10495645B2 (en)	2015-01-16	2019-12-03	Academia Sinica	Cancer markers and methods of use thereof
US20160208018A1 (en)	2015-01-16	2016-07-21	Juno Therapeutics, Inc.	Antibodies and chimeric antigen receptors specific for ror1
US9975965B2 (en)	2015-01-16	2018-05-22	Academia Sinica	Compositions and methods for treatment and detection of cancers
GB201501004D0 (en)	2015-01-21	2015-03-04	Cancer Rec Tech Ltd	Inhibitors
JP2018511557A (ja)	2015-01-22	2018-04-26	中外製薬株式会社	２種以上の抗ｃ５抗体の組み合わせおよび使用方法
KR102630294B1 (ko)	2015-01-24	2024-01-26	아카데미아 시니카	암 마커 및 이를 사용하는 방법
KR20170104617A (ko)	2015-01-24	2017-09-15	아카데미아 시니카	신규한 글리칸 콘주게이트 및 이를 사용하는 방법
JP2018508481A (ja)	2015-02-02	2018-03-29	ザユニバーシティオブバーミンガム	複数のｔ細胞エピトープを有する標的化部分ペプチドエピトープ複合体
JP2018512597A (ja)	2015-02-04	2018-05-17	ジェネンテック，インコーポレイテッド	突然変異体スムースンド及びその使用方法
CN114773469A (zh)	2015-02-05	2022-07-22	中外制药株式会社	包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
US10227411B2 (en)	2015-03-05	2019-03-12	Xencor, Inc.	Modulation of T cells with bispecific antibodies and FC fusions
MA41959A (fr) *	2015-04-21	2018-02-28	Abbvie Stemcentrx Llc	Constructions de calichéamicine d'acide nucléique et leurs procédés d'utilisation
WO2016172485A2 (en)	2015-04-24	2016-10-27	Genentech, Inc.	Multispecific antigen-binding proteins
JP7044553B2 (ja)	2015-04-24	2022-03-30	ジェネンテック，インコーポレイテッド	結合ポリペプチドを含む細菌を特定する方法
JP2018520642A (ja)	2015-05-01	2018-08-02	ジェネンテック，インコーポレイテッド	マスク抗ｃｄ３抗体及びその使用方法
CN116196414A (zh)	2015-05-11	2023-06-02	豪夫迈·罗氏有限公司	治疗狼疮性肾炎的组合物和方法
IL295002A (en)	2015-05-12	2022-09-01	Genentech Inc	Therapeutic and diagnostic methods for cancer containing a pd–l1 binding antagonist
WO2016196343A1 (en)	2015-05-29	2016-12-08	Genentech, Inc.	Humanized anti-ebola virus glycoprotein antibodies and methods of use
KR20180012753A (ko)	2015-05-29	2018-02-06	제넨테크, 인크.	암에 대한 치료 및 진단 방법
KR20180025888A (ko)	2015-06-08	2018-03-09	제넨테크, 인크.	항-ox40 항체 및 pd-1 축 결합 길항제를 사용하여 암을 치료하는 방법
AU2016274585A1 (en)	2015-06-08	2017-12-14	Genentech, Inc.	Methods of treating cancer using anti-OX40 antibodies
CN107847568B (zh)	2015-06-16	2022-12-20	豪夫迈·罗氏有限公司	抗cll-1抗体和使用方法
WO2016204966A1 (en)	2015-06-16	2016-12-22	Genentech, Inc.	Anti-cd3 antibodies and methods of use
PE20180330A1 (es)	2015-06-16	2018-02-13	Genentech Inc	Anticuerpos madurados por afinidad y humanizados para fcrh5 y metodos para su uso
JP2018524312A (ja)	2015-06-17	2018-08-30	ジェネンテック，インコーポレイテッド	抗ｈｅｒ２抗体及び使用方法
CN113999312A (zh)	2015-06-24	2022-02-01	豪夫迈·罗氏有限公司	具有定制亲和力的抗转铁蛋白受体抗体
CN108473573A (zh)	2015-06-29	2018-08-31	豪夫迈·罗氏有限公司	Ii型抗cd20抗体用于器官移植中
NZ739830A (en)	2015-07-12	2021-12-24	Hangzhou Dac Biotech Co Ltd	Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en)	2015-07-15	2017-12-12	Suzhou M-Conj Biotech Co., Ltd.	Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
US10669343B2 (en)	2015-08-05	2020-06-02	Janssen Biotech, Inc.	Anti-CD154 antibodies and methods of using them
CN105384825B (zh)	2015-08-11	2018-06-01	南京传奇生物科技有限公司	一种基于单域抗体的双特异性嵌合抗原受体及其应用
EP3337816B1 (de)	2015-08-20	2024-02-14	Albumedix Ltd	Albumin-varianten und -konjugate
AU2016326666B2 (en)	2015-09-23	2023-06-15	Genentech, Inc.	Optimized variants of anti-VEGF antibodies
CN108289954B (zh)	2015-09-24	2022-05-31	阿布维特罗有限责任公司	Hiv抗体组合物和使用方法
AU2016329057A1 (en)	2015-09-30	2018-04-12	Janssen Biotech, Inc.	Antagonistic antibodies specifically binding human CD40 and methods of use
KR102146319B1 (ko)	2015-10-02	2020-08-25	에프. 호프만-라 로슈 아게	Pd1 및 tim3에 특이적인 이중특이성 항체
DK3356404T3 (da)	2015-10-02	2021-10-25	Hoffmann La Roche	Anti-pd1-antistoffer og fremgangsmåder til anvendelse
AR106189A1 (es)	2015-10-02	2017-12-20	Hoffmann La Roche	ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
AU2016333512B2 (en)	2015-10-02	2022-11-17	F. Hoffmann-La Roche Ag	Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
MA43354A (fr)	2015-10-16	2018-08-22	Genentech Inc	Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr)	2015-10-20	2018-08-29	Genentech Inc	Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
EP3184547A1 (de)	2015-10-29	2017-06-28	F. Hoffmann-La Roche AG	Anti-tpbg-antikörper und verfahren zur verwendung
PL3368579T3 (pl)	2015-10-30	2022-03-21	F. Hoffmann-La Roche Ag	Fragmenty przeciwciał ze zmodyfikowanymi regionami zawiasowymi i sposoby ich wytwarzania
RS63125B1 (sr)	2015-11-03	2022-05-31	Janssen Biotech Inc	Antitela koja se specifično vezuju za pd-1 i njihova upotreba
WO2017079768A1 (en)	2015-11-08	2017-05-11	Genentech, Inc.	Methods of screening for multispecific antibodies
PT3377103T (pt)	2015-11-19	2021-05-26	Revitope Ltd	Complementação de fragmento de anticorpo funcional para um sistema de dois componentes para exterminação redirecionada de células indesejadas
WO2017095823A1 (en)	2015-11-30	2017-06-08	The Regents Of The University Of California	Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
CA3007030A1 (en)	2015-12-07	2017-06-15	Xencor, Inc.	Heterodimeric antibodies that bind cd3 and psma
EP3178848A1 (de)	2015-12-09	2017-06-14	F. Hoffmann-La Roche AG	Type ii anti-cd20 antikörper zur verringerung der bildung von antikörpern gegen medikamente
AU2016368469B2 (en)	2015-12-09	2023-11-02	F. Hoffmann-La Roche Ag	Type II anti-CD20 antibody for reducing formation of anti-drug antibodies
KR102467124B1 (ko)	2015-12-18	2022-11-15	추가이 세이야쿠 가부시키가이샤	항-c5 항체 및 사용 방법
US11414477B2 (en)	2016-01-27	2022-08-16	Medimmune, Llc	Methods for preparing antibodies with a defined glycosylation pattern
CN109071625A (zh)	2016-02-04	2018-12-21	柯瑞斯公司	平滑化突变体和其使用方法
PT3411076T (pt)	2016-02-05	2021-06-17	Rigshospitalet	Conjugados anticorpo-fármaco que têm como alvo uparap
AU2017225854B2 (en)	2016-02-29	2020-11-19	Foundation Medicine, Inc.	Therapeutic and diagnostic methods for cancer
EP3427055A1 (de)	2016-03-07	2019-01-16	Pierre Fabre Medicament	Neues universelles verfahren zur aufnahme und analyse von adcs zur charakterisierung der wirkstoffverteilung und des wirkstoff-antikörper-verhältnisses bei biologischen proben
AU2017231749A1 (en)	2016-03-08	2018-09-20	Academia Sinica	Methods for modular synthesis of N-glycans and arrays thereof
US20170281758A1 (en) *	2016-03-29	2017-10-05	Sorrento Therapeutics, Inc.	Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin
EP3865511A1 (de)	2016-04-14	2021-08-18	F. Hoffmann-La Roche AG	Anti-rspo3-antikörper und verfahren zur verwendung
MX2018012492A (es)	2016-04-15	2019-06-06	Genentech Inc	Métodos para monitorear y tratar el cáncer.
EP3443012A4 (de)	2016-04-15	2019-09-11	Bioatla, LLC	Anti-axl-antikörper, antikörperfragmente und deren immunkonjugate und verwendungen davon
CA3020864A1 (en)	2016-04-15	2017-10-19	Macrogenics, Inc.	Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
AU2017248766A1 (en)	2016-04-15	2018-11-01	Genentech, Inc.	Methods for monitoring and treating cancer
AU2017259869A1 (en)	2016-05-02	2018-09-27	F. Hoffmann-La Roche Ag	The contorsbody - a single chain target binder
WO2017196847A1 (en)	2016-05-10	2017-11-16	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
JP7089483B2 (ja)	2016-05-11	2022-06-22	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	修飾された抗テネイシン抗体及び使用方法
RS63698B1 (sr)	2016-05-13	2022-11-30	Bioatla Inc	Anti-ror2 antitela, fragmenti antitela, njihovi imunokonjugati i njihove upotrebe
EP3465221B1 (de)	2016-05-27	2020-07-22	H. Hoffnabb-La Roche Ag	Bioanalytisches verfahren zur charakterisierung von ortsspezifischen antikörper-wirkstoff-konjugaten
WO2017207540A1 (en)	2016-05-30	2017-12-07	Toxinvent Oü	Antibody-drug-conjugates comprising novel anthracycline-derivatives for cancer treatment
CN110603266A (zh)	2016-06-02	2019-12-20	豪夫迈·罗氏有限公司	用于治疗癌症的ii型抗cd20抗体和抗cd20/cd3双特异性抗体
EP3252078A1 (de)	2016-06-02	2017-12-06	F. Hoffmann-La Roche AG	Typ ii anti-cd20 antikörper und anti-cd20/cd3 bispecific antikörper zur behandlung von krebs
WO2017214182A1 (en)	2016-06-07	2017-12-14	The United States Of America. As Represented By The Secretary, Department Of Health & Human Services	Fully human antibody targeting pdi for cancer immunotherapy
LT3458479T (lt)	2016-06-08	2021-02-25	Abbvie Inc.	Anti-b7-h3 antikūnai ir antikūnų vaisto konjugatai
MX2018015272A (es)	2016-06-08	2019-08-12	Abbvie Inc	Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
CA3027033A1 (en)	2016-06-08	2017-12-14	Abbvie Inc.	Anti-cd98 antibodies and antibody drug conjugates
JP2019521973A (ja)	2016-06-08	2019-08-08	アッヴィ・インコーポレイテッド	抗ｂｈ７−ｈ３抗体及び抗体薬物コンジュゲート
BR112018075653A2 (pt)	2016-06-08	2019-08-27	Abbvie Inc	anticorpos anti-b7-h3 e conjugados anticorpo fármaco
JP7148504B2 (ja)	2016-06-08	2022-10-05	ゼンコー，インコーポレイティド	ＣＤ３２Ｂに交差結合した抗ＣＤ１９抗体を用いたＩｇＧ４関連疾患の治療
WO2017218707A2 (en)	2016-06-14	2017-12-21	Xencor, Inc.	Bispecific checkpoint inhibitor antibodies
WO2018004338A1 (en)	2016-06-27	2018-01-04	Tagworks Pharmaceuticals B.V.	Cleavable tetrazine used in bio-orthogonal drug activation
KR20190020341A (ko)	2016-06-28	2019-02-28	젠코어 인코포레이티드	소마토스타틴 수용체 2에 결합하는 이종이량체 항체
WO2018009811A1 (en)	2016-07-08	2018-01-11	Genentech, Inc.	Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment
CA3031734A1 (en)	2016-07-29	2018-02-01	Juno Therapeutics, Inc.	Anti-idiotypic antibodies against anti-cd19 antibodies
US11066479B2 (en)	2016-08-02	2021-07-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
WO2018025168A1 (en)	2016-08-03	2018-02-08	Pfizer Inc.	Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates
SG11201801024XA (en)	2016-08-05	2018-05-30	Chugai Pharmaceutical Co Ltd	Therapeutic or preventive compositions for il-8-related diseases
JP2019530434A (ja)	2016-08-05	2019-10-24	ジェネンテック，インコーポレイテッド	アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
CN109963868B (zh)	2016-08-22	2023-11-14	醣基生医股份有限公司	抗体、结合片段及使用方法
CN109790220A (zh)	2016-08-25	2019-05-21	豪夫迈·罗氏有限公司	与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
US10793632B2 (en)	2016-08-30	2020-10-06	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
SG10201607778XA (en)	2016-09-16	2018-04-27	Chugai Pharmaceutical Co Ltd	Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2018050878A1 (en)	2016-09-19	2018-03-22	F. Hoffmann-La Roche Ag	Complement factor based affinity chromatography
KR20190072528A (ko)	2016-10-06	2019-06-25	제넨테크, 인크.	암에 대한 치료 및 진단 방법
JP7142630B2 (ja)	2016-10-14	2022-09-27	ゼンコアインコーポレイテッド	ＩＬ１５／ＩＬ１５Ｒαヘテロ二量体ＦＣ－融合タンパク質
MX2019004690A (es)	2016-10-19	2019-09-27	Invenra Inc	Constructos de anticuerpos.
EP3532091A2 (de)	2016-10-29	2019-09-04	H. Hoffnabb-La Roche Ag	Anti-mic-antikörper und verfahren zur verwendung
KR20220147721A (ko)	2016-11-14	2022-11-03	항저우 디에이씨 바이오테크 씨오, 엘티디	결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
CA3042435A1 (en)	2016-11-15	2018-05-24	Genentech, Inc.	Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
TW201829463A (zh)	2016-11-18	2018-08-16	瑞士商赫孚孟拉羅股份公司	抗hla-g抗體及其用途
AU2017361887B2 (en)	2016-11-21	2019-08-15	Cureab Gmbh	Anti-GP73 antibodies and immunoconjugates
US11135307B2 (en)	2016-11-23	2021-10-05	Mersana Therapeutics, Inc.	Peptide-containing linkers for antibody-drug conjugates
US11236171B2 (en)	2016-12-21	2022-02-01	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibodies specific for FLT3 and uses thereof
CN110072553B (zh)	2016-12-22	2023-09-15	豪夫迈·罗氏有限公司	在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
JP2020506716A (ja)	2016-12-22	2020-03-05	ウニヴェルシタ・デリ・ストゥディ・マニャ・グレチア・カタンツァーロ	Ｃｄ４３の固有のシアログリコシル化がん関連エピトープを標的化するモノクローナル抗体
CN110461860A (zh) *	2017-01-24	2019-11-15	辉瑞公司	卡奇霉素衍生物及其抗体药物缀合物
JP6995127B2 (ja)	2017-02-10	2022-02-04	ジェネンテック，インコーポレイテッド	抗トリプターゼ抗体、その組成物、及びその使用
CA3052670A1 (en)	2017-03-01	2018-09-07	Genentech, Inc.	Diagnostic and therapeutic methods for cancer
JP2020517695A (ja)	2017-04-27	2020-06-18	テサロ，インコーポレイテッド	リンパ球活性化遺伝子−３（ｌａｇ−３）に対する抗体薬およびそれらの使用
EP3625256A1 (de)	2017-05-19	2020-03-25	The U.S.A. as represented by the Secretary, Department of Health and Human Services	Humaner monoklonaler antikörper gegen tnfr2 zur krebsimmuntherapie
AR111963A1 (es)	2017-05-26	2019-09-04	Univ California	Método y moléculas
TW201905037A (zh)	2017-06-22	2019-02-01	美商梅爾莎納醫療公司	藥物攜帶聚合物支架及蛋白質聚合物藥物共軛物之製造方法
WO2019005208A1 (en)	2017-06-30	2019-01-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
US11084863B2 (en)	2017-06-30	2021-08-10	Xencor, Inc.	Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
WO2019006280A1 (en)	2017-06-30	2019-01-03	Lentigen Technology, Inc.	HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
US20190048073A1 (en)	2017-07-20	2019-02-14	Pfizer Inc.	Anti-gd3 antibodies and antibody-drug conjugates
TWI823859B (zh)	2017-07-21	2023-12-01	美商建南德克公司	癌症之治療及診斷方法
JP7232190B2 (ja)	2017-10-20	2023-03-02	中外製薬株式会社	細胞への分子の取り込みを測定する方法
MX2020004100A (es)	2017-10-30	2020-07-24	Hoffmann La Roche	Metodo para generacion in vivo de anticuerpos multiespecificos a partir de anticuerpos monoespecificos.
MA49911A (fr)	2017-11-01	2020-06-24	Juno Therapeutics Inc	Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
AU2018358904A1 (en)	2017-11-01	2020-04-16	F. Hoffmann-La Roche Ag	TriFab-contorsbody
JP2021500930A (ja)	2017-11-01	2021-01-14	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Ｃｏｍｐボディ−多価標的結合物質
AU2018359967A1 (en)	2017-11-06	2020-04-23	Genentech, Inc.	Diagnostic and therapeutic methods for cancer
US10981992B2 (en)	2017-11-08	2021-04-20	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11312770B2 (en)	2017-11-08	2022-04-26	Xencor, Inc.	Bispecific and monospecific antibodies using novel anti-PD-1 sequences
WO2019125732A1 (en)	2017-12-19	2019-06-27	Xencor, Inc.	Engineered il-2 fc fusion proteins
JP7314146B2 (ja)	2017-12-28	2023-07-25	中外製薬株式会社	細胞傷害誘導治療剤
US20200339686A1 (en)	2018-01-16	2020-10-29	Lakepharma, Inc.	Bispecific antibody that binds cd3 and another target
MA51793A (fr)	2018-02-08	2020-12-16	Hoffmann La Roche	Molécules bispécifiques de liaison à l'antigène et procédés d'utilisation
TW202000702A (zh)	2018-02-26	2020-01-01	美商建南德克公司	用於抗ｔｉｇｉｔ拮抗劑抗體及抗ｐｄ－ｌ１拮抗劑抗體治療之投藥
EA202092044A1 (ru)	2018-03-14	2021-03-03	Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез	Химерные рецепторы антигена против cd33 и их применения
US20200040103A1 (en)	2018-03-14	2020-02-06	Genentech, Inc.	Anti-klk5 antibodies and methods of use
CN112119090B (zh)	2018-03-15	2023-01-13	中外制药株式会社	对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
JP7104458B2 (ja)	2018-04-02	2022-07-21	上海博威生物医薬有限公司	リンパ球活性化遺伝子－３（ｌａｇ－３）結合抗体およびその使用
TW202011029A (zh)	2018-04-04	2020-03-16	美商建南德克公司	偵測及定量fgf21之方法
EP3773911A2 (de)	2018-04-04	2021-02-17	Xencor, Inc.	Heterodimere antikörper, die das fibroblastenaktivierungsprotein binden
AR114789A1 (es)	2018-04-18	2020-10-14	Hoffmann La Roche	Anticuerpos anti-hla-g y uso de los mismos
CA3097741A1 (en)	2018-04-18	2019-10-24	Xencor, Inc.	Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
JP2021521784A (ja)	2018-04-18	2021-08-30	ゼンコアインコーポレイテッド	ＩＬ−１５／ＩＬ−１５ＲａＦｃ融合タンパク質とＰＤ−１抗原結合ドメインを含むＰＤ−１標的化ヘテロダイマー融合タンパク質およびそれらの使用
WO2019212356A1 (en)	2018-05-04	2019-11-07	Tagworks Pharmaceuticals B .V.	Tetrazines for high click conjugation yield in vivo and high click release yield
EP3788032B1 (de)	2018-05-04	2024-01-24	Tagworks Pharmaceuticals B.V.	Verbindungen mit einem linker zur erhöhung der transcyclooctenstabilität
ES2955511T3 (es)	2018-05-14	2023-12-04	Werewolf Therapeutics Inc	Polipéptidos de interleucina 2 activables y métodos de uso de los mismos
AU2019271149B2 (en)	2018-05-14	2023-07-13	Werewolf Therapeutics, Inc.	Activatable interleukin 12 polypeptides and methods of use thereof
WO2019224718A2 (en)	2018-05-24	2019-11-28	Janssen Biotech, Inc.	Psma binding agents and uses thereof
CA3102349A1 (en)	2018-06-05	2019-12-12	King's College London	Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
CN112584859A (zh)	2018-07-02	2021-03-30	美国安进公司	抗steap1抗原结合蛋白
JP7459043B2 (ja)	2018-07-12	2024-04-01	ザユナイテッドステイツオブアメリカ，アズリプレゼンテッドバイザセクレタリー，デパートメントオブヘルスアンドヒューマンサービシーズ	親和性成熟ｃｄ２２特異的モノクローナル抗体およびその使用
CN112585163A (zh)	2018-08-08	2021-03-30	美国政府(由卫生和人类服务部的部长所代表)	靶向磷脂酰肌醇蛋白聚糖-2的高亲和力单克隆抗体及其用途
EA202190451A1 (ru)	2018-08-10	2021-07-13	Чугаи Сейяку Кабусики Кайся	Анти-cd137 антигенсвязывающие молекулы и их применение
WO2020056170A1 (en)	2018-09-12	2020-03-19	Fred Hutchinson Cancer Research Center	Reducing cd33 expression to selectively protect therapeutic cells
JP2022501332A (ja)	2018-09-19	2022-01-06	ジェネンテック，インコーポレイテッド	膀胱がんの治療方法および診断方法
CA3114137A1 (en)	2018-09-26	2020-04-02	Jiangsu Hengrui Medicine Co., Ltd.	Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof
WO2020069398A1 (en)	2018-09-27	2020-04-02	Akrevia Therapeutics Inc.	Masked cytokine polypeptides
CN113195523A (zh)	2018-10-03	2021-07-30	Xencor股份有限公司	IL-12异源二聚体Fc融合蛋白
WO2020081767A1 (en)	2018-10-18	2020-04-23	Genentech, Inc.	Diagnostic and therapeutic methods for sarcomatoid kidney cancer
EP3873534A1 (de)	2018-10-29	2021-09-08	Mersana Therapeutics, Inc.	Cystein-modifizierte antikörper-wirkstoff-konjugate mit peptidhaltigen linkern
JP2022512882A (ja)	2018-11-07	2022-02-07	クリスパーセラピューティクスアクチェンゲゼルシャフト	抗ｃｄ３３免疫細胞癌療法
CN113056288A (zh)	2018-11-20	2021-06-29	康奈尔大学	放射性核素的大环配合物及其在癌症的放射治疗中的应用
WO2020117257A1 (en)	2018-12-06	2020-06-11	Genentech, Inc.	Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody
WO2020127968A1 (en)	2018-12-20	2020-06-25	Marino Stephen F	Protein-drug conjugate comprising a monomeric form of proteinase 3
JP2022514290A (ja)	2018-12-20	2022-02-10	ジェネンテック，インコーポレイテッド	改変抗体ｆｃおよび使用方法
KR20210141447A (ko)	2018-12-26	2021-11-23	실리오 디벨럽먼트, 인크.	항-ctla4 항체 및 이의 사용 방법
EP3883608A1 (de)	2019-01-08	2021-09-29	The United States of America, as represented by the Secretary, Department of Health and Human Services	Speziesübergreifende einzeldomänenantikörper gegen mesothelin zur behandlung von soliden tumoren
CN113784987A (zh)	2019-01-22	2021-12-10	美国政府(由卫生和人类服务部的部长所代表)	靶向磷脂酰肌醇蛋白聚糖-1的高亲和力单克隆抗体和使用方法
EP3914291A2 (de)	2019-01-22	2021-12-01	F. Hoffmann-La Roche AG	Immunoglobulin-a-antikörper und verfahren zur herstellung und verwendung
EP3915581A4 (de)	2019-01-24	2023-03-22	Chugai Seiyaku Kabushiki Kaisha	Neuartige krebsantigene und antikörper dieser antigene
US20220096651A1 (en)	2019-01-29	2022-03-31	Juno Therapeutics, Inc.	Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
MX2021010313A (es)	2019-02-27	2021-09-23	Genentech Inc	Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38.
WO2020180726A1 (en)	2019-03-01	2020-09-10	Xencor, Inc.	Heterodimeric antibodies that bind enpp3 and cd3
CA3130446A1 (en)	2019-03-14	2020-09-17	Genentech, Inc.	Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab
WO2020187998A1 (en)	2019-03-19	2020-09-24	Fundació Privada Institut D'investigació Oncològica De Vall Hebron	Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
AU2020258480A1 (en)	2019-04-19	2021-10-21	Genentech, Inc.	Anti-mertk antibodies and their methods of use
AR118720A1 (es)	2019-04-19	2021-10-27	Janssen Biotech Inc	Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
JP2022532217A (ja)	2019-05-14	2022-07-13	ウェアウルフセラピューティクス，インコーポレイテッド	分離部分及びその使用方法
AU2020275415A1 (en)	2019-05-14	2021-11-25	Genentech, Inc.	Methods of using anti-CD79B immunoconjugates to treat follicular lymphoma
AU2020275348A1 (en)	2019-05-15	2021-12-09	Chugai Seiyaku Kabushiki Kaisha	An antigen-binding molecule, a pharmaceutical composition, and a method
EP3976111A4 (de)	2019-06-03	2023-07-05	The University of Chicago	Verfahren und zusammensetzungen zur behandlung von krebs mit kollagenbindenden arzneimittelträgern
EP3983406A4 (de) *	2019-06-12	2023-09-06	Ontario Institute for Cancer Research (OICR)	Ungesättigte heterocycloalkyl- und heteroaromatische acylhydrazon-linker, verfahren und ihre verwendungen
JP2022537543A (ja)	2019-06-17	2022-08-26	タグワークスファーマシューティカルスビー．ブイ．	高速で且つ効率的なクリック放出の為の化合物
IL289094A (en)	2019-06-17	2022-02-01	Tagworks Pharmaceuticals B V	Tetrazines for increasing the speed and yield of the "click release" reaction
CA3139250A1 (en)	2019-07-10	2021-01-14	Naoki Kimura	Claudin-6 binding molecules and uses thereof
CN114341187A (zh)	2019-07-12	2022-04-12	中外制药株式会社	抗突变型fgfr3抗体及其用途
EP4013875A1 (de)	2019-08-14	2022-06-22	Codiak BioSciences, Inc.	Extrazelluläre vesikel mit stat3-anti-sense-oligonukleotiden
CN114729356A (zh)	2019-08-14	2022-07-08	科迪亚克生物科学公司	靶向stat6的细胞外囊泡-aso构建体
US20230002764A1 (en)	2019-08-14	2023-01-05	Codiak Biosciences, Inc.	Extracellular vesicle-aso constructs targeting cebp/beta
JP2022544935A (ja)	2019-08-14	2022-10-24	コディアックバイオサイエンシーズ，インコーポレイテッド	細胞外小胞－ｎｌｒｐ３アンタゴニスト
BR112022003635A2 (pt)	2019-09-04	2022-05-24	Pf Medicament	Anticorpo anti-vsig4 ou fragmento de ligação ao antígeno e seu uso
JP2022548978A (ja)	2019-09-27	2022-11-22	ジェネンテック，インコーポレイテッド	薬抗ｔｉｇｉｔ及び抗ｐｄ－ｌ１アンタゴニスト抗体を用いた処置のための投薬
US20240058466A1 (en)	2019-10-04	2024-02-22	TAE Life Sciences	Antibody Compositions Comprising Fc Mutations and Site-Specific Conjugation Properties For Use In Treating Cancer, Immunological Disorders, and Methods Thereof
JP7413519B2 (ja)	2019-10-18	2024-01-15	ジェネンテック，インコーポレイテッド	びまん性大細胞型ｂ細胞リンパ腫を処置するための抗ｃｄ７９ｂ免疫抱合体の使用方法
AU2020370125A1 (en)	2019-10-22	2022-05-19	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	High affinity nanobodies targeting B7H3 (CD276) for treating multiple solid tumors
IL292458A (en)	2019-11-06	2022-06-01	Genentech Inc	Diagnostic and treatment methods for the treatment of hematological cancer
JP2023550743A (ja)	2019-11-22	2023-12-05	メドイミューン・リミテッド	Ｅ２ユビキチン又はユビキチン様コンジュゲートドメインを含む融合タンパク質並びに特定のタンパク質分解のためのドメインの標的化
CA3163897A1 (en)	2019-12-06	2021-06-10	Juno Therapeutics, Inc.	Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
KR20220122656A (ko)	2019-12-06	2022-09-02	주노 쎄러퓨티크스 인코퍼레이티드	Ｇｐｒｃ5ｄ-표적화 결합 도메인에 대한 항-이디오타입 항체 및 관련 조성물 및 방법
EP4041769A1 (de)	2019-12-12	2022-08-17	The United States of America, as represented by the Secretary, Department of Health and Human Services	Antikörper-wirkstoff-konjugate spezifisch für cd276 und deren verwendungen
AU2020403145A1 (en)	2019-12-13	2022-07-07	Genentech, Inc.	Anti-Ly6G6D antibodies and methods of use
AU2019479791A1 (en)	2019-12-27	2022-07-14	Chugai Seiyaku Kabushiki Kaisha	Anti-CTLA-4 antibody and use thereof
CN110818795B (zh)	2020-01-10	2020-04-24	上海复宏汉霖生物技术股份有限公司	抗tigit抗体和使用方法
TW202140078A (zh)	2020-01-22	2021-11-01	大陸商上海森輝醫藥有限公司	艾日布林衍生物的藥物偶聯物、其製備方法及其在醫藥上的應用
WO2022050954A1 (en)	2020-09-04	2022-03-10	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021194481A1 (en)	2020-03-24	2021-09-30	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
TW202144395A (zh)	2020-02-12	2021-12-01	日商中外製藥股份有限公司	用於癌症之治療的抗cd137抗原結合分子
IL296256A (en)	2020-03-13	2022-11-01	Genentech Inc	Antibodies against interleukin-33 and uses thereof
CN117510630A (zh)	2020-03-19	2024-02-06	基因泰克公司	同种型选择性抗TGF-β抗体及使用方法
BR112022019042A2 (pt)	2020-03-25	2022-11-01	Jiangsu Hengrui Pharmaceuticals Co Ltd	Método de preparação para conjugado anticorpo-fármaco
JP2023518583A (ja)	2020-03-25	2023-05-02	江蘇恒瑞医薬股▲ふん▼有限公司	抗体薬物複合体を含む医薬組成物及びその使用本願は、２０２０年３月２５日に提出された中国特許出願（出願番号ｃｎ２０２０１０２１９６０１．７）及び２０２１年３月１７日に提出された中国特許出願（出願番号ｃｎ２０２１１０２８７０１２．７）の優先権を主張する。
WO2021202959A1 (en)	2020-04-03	2021-10-07	Genentech, Inc.	Therapeutic and diagnostic methods for cancer
IL297541A (en)	2020-04-24	2022-12-01	Genentech Inc	Methods for using anti-cd79b immunoconjugates
WO2021222167A1 (en)	2020-04-28	2021-11-04	Genentech, Inc.	Methods and compositions for non-small cell lung cancer immunotherapy
US11919956B2 (en)	2020-05-14	2024-03-05	Xencor, Inc.	Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
US20230220068A1 (en)	2020-06-05	2023-07-13	Codiak Biosciences, Inc.	Anti-transferrin extracellular vesicles
BR112022025227A2 (pt)	2020-06-11	2023-01-03	Genentech Inc	Conjugados, composição farmacêutica, formulação líquida, métodos para preparar um conjugado, para aumentar a estabilidade, para tratar um indivíduo, para entregar um polipeptídeo de ligação, para entregar um peptídeo curto, para entregar um agente biologicamente ativo, método para reduzir a conjugação lipídio-proteína-esqueleto e método para aumentar a atividade biológica, uso do conjugado e sistema ou kit
WO2021252977A1 (en)	2020-06-12	2021-12-16	Genentech, Inc.	Methods and compositions for cancer immunotherapy
KR20230024368A (ko)	2020-06-18	2023-02-20	제넨테크, 인크.	항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료
CN115812149A (zh)	2020-07-13	2023-03-17	基因泰克公司	用于预测多肽免疫原性的基于细胞的方法
US20230296612A1 (en)	2020-07-29	2023-09-21	Chugai Seiyaku Kabushiki Kaisha	Method for measuring pharmacokinetics of agent labeled with non-radioactive substance
JP2023536326A (ja)	2020-08-05	2023-08-24	ジュノーセラピューティクスインコーポレイテッド	Ｒｏｒ１標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法
MX2023001440A (es)	2020-08-07	2023-03-06	Genentech Inc	Proteinas de fusion del ligando para flt3 y metodos de uso.
WO2022031948A1 (en)	2020-08-07	2022-02-10	Genentech, Inc.	T cell-based methods for predicting polypeptide immunogenicity
US20230372484A1 (en)	2020-09-14	2023-11-23	Vor Biopharma Inc.	Chimeric antigen receptors for treatment of cancer
CN116406291A (zh)	2020-10-05	2023-07-07	基因泰克公司	用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
WO2022093745A1 (en)	2020-10-26	2022-05-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Single domain antibodies targeting sars coronavirus spike protein and uses thereof
US20240000846A1 (en)	2020-10-27	2024-01-04	Vor Biopharma Inc.	Compositions and methods for treating hematopoietic malignancy
CA3196539A1 (en)	2020-11-04	2022-05-12	Chi-Chung Li	Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
AU2021374594A1 (en)	2020-11-04	2023-06-01	Genentech, Inc.	Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
CA3196076A1 (en)	2020-11-04	2022-05-12	Chi-Chung Li	Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
AR124681A1 (es)	2021-01-20	2023-04-26	Abbvie Inc	Conjugados anticuerpo-fármaco anti-egfr
US20240059789A1 (en)	2021-01-28	2024-02-22	Janssen Biotech, Inc.	Psma binding proteins and uses thereof
CA3209364A1 (en)	2021-03-01	2022-09-09	Jennifer O'neil	Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
WO2022187270A1 (en)	2021-03-01	2022-09-09	Xilio Development, Inc.	Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
KR20230156727A (ko)	2021-03-03	2023-11-14	피에르 파브르 메디카먼트	항-vsig4 항체 또는 이의 항원 결합 단편 및 용도
WO2022192403A1 (en)	2021-03-09	2022-09-15	Xencor, Inc.	Heterodimeric antibodies that bind cd3 and cldn6
KR20230154311A (ko)	2021-03-10	2023-11-07	젠코어 인코포레이티드	Cd3 및 gpc3에 결합하는 이종이량체 항체
AR125344A1 (es)	2021-04-15	2023-07-05	Chugai Pharmaceutical Co Ltd	Anticuerpo anti-c1s
WO2022232612A1 (en)	2021-04-29	2022-11-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Lassa virus-specific nanobodies and methods of their use
KR20240037188A (ko)	2021-04-30	2024-03-21	피에르 파브르 메디카먼트	신규의 안정한 항-vista 항체
KR20240005691A (ko)	2021-04-30	2024-01-12	에프. 호프만-라 로슈 아게	항-cd20/항-cd3 이중특이적 항체 및 항-cd79b 항체 약물 접합체를 이용한 병용 치료를 위한 투약
AU2021443863A1 (en)	2021-04-30	2023-10-26	F. Hoffmann-La Roche Ag	Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
CA3218170A1 (en)	2021-05-12	2022-11-17	Jamie Harue HIRATA	Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
EP4342984A1 (de)	2021-05-19	2024-03-27	Chugai Seiyaku Kabushiki Kaisha	Verfahren zur vorhersage der in-vivo-pharmazekinetik eines moleküls
BR112023024804A2 (pt)	2021-05-28	2024-02-15	Glaxosmithkline Ip Dev Ltd	Terapias de combinação para tratar câncer
TW202306994A (zh)	2021-06-04	2023-02-16	日商中外製藥股份有限公司	抗ddr2抗體及其用途
CA3216228A1 (en)	2021-06-09	2022-12-15	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Cross species single domain antibodies targeting pd-l1 for treating solid tumors
EP4361176A1 (de)	2021-06-25	2024-05-01	Chugai Seiyaku Kabushiki Kaisha	Verwendung eines anti-ctla-4-antikörpers
EP4361273A1 (de)	2021-06-25	2024-05-01	Chugai Seiyaku Kabushiki Kaisha	Anti-ctla-4-antikörper
US11807685B2 (en)	2021-08-05	2023-11-07	The Uab Research Foundation	Anti-CD47 antibody and uses thereof
WO2023019092A1 (en)	2021-08-07	2023-02-16	Genentech, Inc.	Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
WO2023017159A1 (en)	2021-08-13	2023-02-16	Ludwig-Maximilians-Universität München	Anti-csf1r car expressing lymphocytes for targeted tumor therapy
WO2023031445A2 (en)	2021-09-06	2023-03-09	Veraxa Biotech Gmbh	Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
WO2023056403A1 (en)	2021-09-30	2023-04-06	Genentech, Inc.	Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
WO2023057893A1 (en)	2021-10-05	2023-04-13	Glaxosmithkline Intellectual Property Development Limited	Combination therapies for treating cancer
EP4186529A1 (de)	2021-11-25	2023-05-31	Veraxa Biotech GmbH	Verbesserte antikörper-nutzlast-konjugate (aps), hergestellt durch ortsspezifische konjugation mittels genetischer codeerweiterung
WO2023094525A1 (en)	2021-11-25	2023-06-01	Veraxa Biotech Gmbh	Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
WO2023104941A1 (en)	2021-12-08	2023-06-15	European Molecular Biology Laboratory	Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
WO2023131901A1 (en)	2022-01-07	2023-07-13	Johnson & Johnson Enterprise Innovation Inc.	Materials and methods of il-1beta binding proteins
WO2023158305A1 (en)	2022-02-15	2023-08-24	Tagworks Pharmaceuticals B.V.	Masked il12 protein
TW202346365A (zh)	2022-03-23	2023-12-01	瑞士商赫孚孟拉羅股份公司	抗ｃｄ２０／抗ｃｄ３雙特異性抗體及化學療法之組合治療
WO2023191816A1 (en)	2022-04-01	2023-10-05	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023198727A1 (en)	2022-04-13	2023-10-19	F. Hoffmann-La Roche Ag	Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
WO2023201299A1 (en)	2022-04-13	2023-10-19	Genentech, Inc.	Pharmaceutical compositions of therapeutic proteins and methods of use
WO2023215293A1 (en)	2022-05-02	2023-11-09	Athanor Biosciences, Inc.	Cancer eradicating – bio-nanoparticles (ce-bnp)
WO2023219613A1 (en)	2022-05-11	2023-11-16	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023240058A2 (en)	2022-06-07	2023-12-14	Genentech, Inc.	Prognostic and therapeutic methods for cancer
WO2024015897A1 (en)	2022-07-13	2024-01-18	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024020432A1 (en)	2022-07-19	2024-01-25	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024020564A1 (en)	2022-07-22	2024-01-25	Genentech, Inc.	Anti-steap1 antigen-binding molecules and uses thereof
WO2024049949A1 (en)	2022-09-01	2024-03-07	Genentech, Inc.	Therapeutic and diagnostic methods for bladder cancer
WO2024073751A1 (en)	2022-09-29	2024-04-04	Vor Biopharma Inc.	Methods and compositions for gene modification and enrichment
WO2024080872A1 (en)	2022-10-12	2024-04-18	Tagworks Pharmaceuticals B.V.	Strained bicyclononenes

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5053394A (en) *	1988-09-21	1991-10-01	American Cyanamid Company	Targeted forms of methyltrithio antitumor agents
EP0329184A3 (de) *	1988-02-19	1990-05-23	Neorx Corporation	Antimere und antimere Konjugation
US5144012A (en) *	1988-08-08	1992-09-01	Eli Lilly And Company	Cytotoxic drug conjugates
US5094849A (en) *	1988-08-08	1992-03-10	Eli Lilly And Company	Cytotoxic antibody conjugates of hydrazide derivatized vinca analogs via simple organic linkers
US5028697A (en) *	1988-08-08	1991-07-02	Eli Lilly And Company	Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
US5006652A (en) *	1988-08-08	1991-04-09	Eli Lilly And Company	Intermediates for antibody-vinca drug conjugates
US5045451A (en) *	1988-10-26	1991-09-03	Board Of Regents	Methods for screening antibodies for use as immunotoxins
IL93733A (en) *	1989-04-14	1996-01-19	American Cyanamid Co	History of Dissolved Drug Sulphides Antibacterial and Antibacterial, Prepared from Compounds Containing Methyl-Thriteo Groups and Their Target Form
GB8928874D0 (en) *	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
GB9120467D0 (en) *	1991-09-26	1991-11-06	Celltech Ltd	Anti-hmfg antibodies and process for their production
US5773001A (en) *	1994-06-03	1998-06-30	American Cyanamid Company	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis

1994
- 1994-06-03 US US08/253,877 patent/US5773001A/en not_active Expired - Lifetime
- 1994-10-12 TW TW083109420A patent/TW394778B/zh not_active IP Right Cessation
1995
- 1995-05-26 US US08/452,164 patent/US5877296A/en not_active Expired - Lifetime
- 1995-05-31 JP JP15564495A patent/JP3650165B2/ja not_active Expired - Lifetime
- 1995-06-01 AT AT95303746T patent/ATE223234T1/de active
- 1995-06-01 CA CA2150785A patent/CA2150785C/en not_active Expired - Lifetime
- 1995-06-01 EP EP95303746A patent/EP0689845B1/de not_active Expired - Lifetime
- 1995-06-01 PT PT95303746T patent/PT689845E/pt unknown
- 1995-06-01 ES ES95303746T patent/ES2181752T3/es not_active Expired - Lifetime
- 1995-06-01 IL IL11398495A patent/IL113984A/xx not_active IP Right Cessation
- 1995-06-01 DE DE69528016T patent/DE69528016T2/de not_active Expired - Lifetime
- 1995-06-01 SI SI9530554T patent/SI0689845T1/xx unknown
- 1995-06-01 DK DK95303746T patent/DK0689845T3/da active
- 1995-06-02 NZ NZ272274A patent/NZ272274A/en not_active IP Right Cessation
- 1995-06-02 NZ NZ536440A patent/NZ536440A/en not_active IP Right Cessation
- 1995-06-02 ZA ZA954570A patent/ZA954570B/xx unknown
- 1995-06-02 AU AU20449/95A patent/AU697280B2/en not_active Expired
- 1995-06-02 NO NO19952206A patent/NO313617B1/no not_active IP Right Cessation
- 1995-06-02 FI FI952720A patent/FI117690B/fi not_active IP Right Cessation
- 1995-06-03 KR KR1019950014699A patent/KR100408376B1/ko not_active IP Right Cessation
- 1995-06-05 US US08/462,939 patent/US5767285A/en not_active Expired - Lifetime
- 1995-06-05 US US08/461,284 patent/US5739116A/en not_active Expired - Lifetime
1997
- 1997-05-14 BR BR1100990-0A patent/BR1100990A/pt active IP Right Grant
- 1997-05-14 BR BR1101078-9A patent/BR1101078A/pt active IP Right Grant
- 1997-09-17 NZ NZ328762A patent/NZ328762A/xx not_active IP Right Cessation
2003
- 2003-01-27 CY CY0300005A patent/CY2334B1/xx unknown
2005
- 2005-01-12 JP JP2005004986A patent/JP2005139200A/ja active Pending

Also Published As

Publication number	Publication date
NO952206D0 (no)	1995-06-02
PT689845E (pt)	2002-12-31
EP0689845B1 (de)	2002-09-04
JPH0848637A (ja)	1996-02-20
FI952720A0 (fi)	1995-06-02
IL113984A (en)	2000-09-28
US5773001A (en)	1998-06-30
AU697280B2 (en)	1998-10-01
US5739116A (en)	1998-04-14
CY2334B1 (en)	2004-02-06
BR1100990A (pt)	2002-04-02
BR1101078A (pt)	1999-10-26
DK0689845T3 (da)	2003-01-06
EP0689845A2 (de)	1996-01-03
ZA954570B (en)	1996-05-22
EP0689845A3 (de)	1999-08-25
NZ328762A (en)	2000-08-25
FI952720A (fi)	1995-12-04
AU2044995A (en)	1995-12-14
ES2181752T3 (es)	2003-03-01
US5767285A (en)	1998-06-16
ATE223234T1 (de)	2002-09-15
CA2150785A1 (en)	1995-12-04
JP3650165B2 (ja)	2005-05-18
NZ272274A (en)	1997-11-24
KR960000234A (ko)	1996-01-25
DE69528016T2 (de)	2003-01-02
NZ536440A (en)	2007-08-31
SI0689845T1 (en)	2002-12-31
CA2150785C (en)	2010-07-06
FI117690B (fi)	2007-01-31
JP2005139200A (ja)	2005-06-02
NO313617B1 (no)	2002-11-04
KR100408376B1 (ko)	2004-03-09
US5877296A (en)	1999-03-02
NO952206L (no)	1995-12-04
TW394778B (en)	2000-06-21
IL113984A0 (en)	1995-10-31

Legal Events

Date	Code	Title	Description
2003-10-02	8364	No opposition during term of opposition
2003-10-09	8327	Change in the person/name/address of the patent owner	Owner name: WYETH HOLDINGS CORP., MADISON, N.J., US

Publication	Publication Date	Title
DE69528016D1 (de)	2002-10-10	Konjugate von Methyltrithio-Antitumormitteln und Zwischenprodukte für deren Herstellung
DE50014571D1 (de)	2007-09-27	Träger-pharmaka-konjugate
IL189629A0 (en)	2008-06-05	Compositions containing human ctla-4 antibodies
TR200003117T2 (tr)	2001-03-21	Hastalıkların tedavisi için arsenik sülfür bileşikleri ve bunların türevleri
MX9304647A (es)	1994-02-28	7-(sustituido)-9-[(glicilo sustituido)amido]-6-desmetil-6-desoxitetraciclinas y metodo para su produccion.
DE69838979D1 (de)	2008-02-21	Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
DE69333800D1 (de)	2005-06-09	Thioether enthaltende Konjugate
DE69533564D1 (de)	2004-11-04	Effektor-Proteine für Rapamycin
HUP0202442A2 (hu)	2002-11-28	Több citokinből és ellenanyagból álló komplexek
GR1000118B (el)	1991-06-28	Συνθεσις 1,2-διοξετανων & ενδιαμεσαι ουσιαι δι αυτην.
ES2123582T3 (es)	1999-01-16	Proteina con capacidad de formacion de huesos y procedimiento para su produccion.
AU1125192A (en)	1993-01-28	Fusion proteins for prodrug activation, the preparation and use thereof
HK1011560A1 (en)	1999-07-16	Method of diagnosing and treating epithelioma
NO176717C (no)	1995-05-16	Analogifremgangsmåte ved fremstilling av målsökende anti-tumorforbindelser
ATE173504T1 (de)	1998-12-15	Granulozytenbindende antikörperkonstrukte, ihre herstellung und verwendung
DE9214709U1 (de)	1994-03-03	Molybdänpulvermischung für TZM
WO2000075190A3 (en)	2001-05-25	Hybridomas for lung cancer marker and monoclonal antibodies thereof
DE29507778U1 (de)	1996-09-19	Keramischer Balken für Tunnelofen-Brennwagen
WO1999032507A3 (en)	1999-09-10	Intermediates and process for the synthesis of 17-unsubstituted 16.beta.-aryloxy 4-azasteroids